




LONG SPAN DNA PAIRED-END TAGS (DNA-PET) FOR UNRAVELING GENOMIC 









A THESIS SUBMITTED  
 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF EPIDEMIOLOGY AND PUBLIC HEALTH 








   
ii 
 
             Acknowledgements 
Cancer is responsible for one in eight deaths worldwide, however, our understanding of 
the cancer genomes is still in early days, and frequently, we only identify the tip of the 
iceberg. In this thesis, I studied few breast and gastric cancer genomes by the long span 
DNA-PET sequencing technology and revealed some characteristic of cancer genomes. 
Of course, this thesis would not have been possible without the help of many people. And 
so, I’d like to thank… 
My parents, family, and friends, for supporting me always. 
Edison Liu and Ruan Yijun, for being my PhD supervisors, and providing me with a lot 
of support. 
Hillmer Axel, for working together with me on this project and the papers. 
Wei Chialin, for giving me all the mentoring and supporting after I joined this group. 
Ruan Xiaoan, for giving me all the supporting and caring.  
Members of Genome Technology and Biology, especially Audrey Teo and  Zhang 
Zhenshui, the DNA-PET library construction team.  
All paper coauthors and people who have contributed to this thesis in one way or another 
(names are not in any particular order): Herve Thoreau, Melvyn Tan, Yow Jit Sin, Dawn 
Choi, Low Hwee Meng, Eleanor Wong, Ong Chin Thing (Jo), Neo Say Chuan, Yap Zhei 
Hwee, Poh Tong Shing, Leong See Ting, Adeline Chew, Jeremiah Decosta, Alexis Khng 
Jiaying, Lim Kian Chew, Zhang Zhenshui,  Audrey Teo, Ruan Yijun, Wei Chia-Lin, 
Ruan Xiaoan,  Edison Liu, Andrea Chavasse, Liu Jun, Patrick Ng, Lee Yen Ling, Jack 
Tan, James Ye, Lim Yan Wei, Isnarti Bte Abdullah, Guillaume Bourque, Valere 
Cacheux-Rataboul, Wing-Kin (Ken) Sung,  Pramila Ariyaratne, Yanquan Luo, Charlie 
Lee, Lusy Handoko, Sim Hui Shan, Axel Hillmer, Goh Yu Fen, Christina Nilsson, Zhang 
Yu Bo, Ngan Chew Yee, Christine Gao, Andrea Ho, Poh Huay Mei,  Koichiro Inaki,  , 
Xing Yi Woo, Zhao Hao, Leena Ukil, Jieqi P. Chen, Feng Zhu, Jimmy B.Y. So, Manuel 
Salto-Tellez, Wan Ting Poh, Kelson F.B. Zawack, Hui Ping J. Lim, Yee Yen Sia, Chee 
Seng Chan, Patrick B.O. Tan, Atif Shahab, Jonas Bergh, Per Hall, Khay Guan Yeoh, 
Lance Miller, Chan Yang Sun, Li Guoliang, Melissa Fullwood. 










1.Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, et al. (2011) Comprehensive long-span   
paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial     
cancer genomes. Genome Res 21: 665-675. * I am the co-first author of this paper. 
 
2. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, et al. (2011) Transcriptional consequences of  
   genomic structural aberrations in breast cancer. Genome Res 21: 676-687. 
 
3. Ng  KP, Hillmer AM, Chuah CT, Juan WC, Yao F, et al. (2012) A common BIM deletion  
    polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in  



























Table of Contents 
Declaration…………………………………………………………………………………………….   i 
Acknowlegements………………………………………………………………………………ii 
Publication list………………………………………………………………………………....iii 
Table of contents……………………………………………………………………………... v 
Summary………………………………………………………………………………………vi 
List of tables…………………………………………………………………………………...vii 
List of figures…………………………………………………………………………………viii 
List of abbreviations and symbols……………………………………………………………. x 
Chapter One: Human cancer genome…………………………………………………………. 1 
Introduction………………………………………………………………………………….2 
    Technologies for detecting cancer genomic SVs…………………………………………….3 
Cytogenetic methods………………………………………………………………………...3 
    Array based methods………………………………………………………………………...4 
PCR based methods………………………………………………………………………… 5 
Sequence based methods…………………………………………………………………… 6 
Chapter Two: Long Span DNA-PET Sequencing Strategy for the Interragation of Genomic     




Chapter Three: Long Span PET Mapping Reveals Characteristic Patterns of Structural  
Variations in Epithelial Cancer Genomes .…………………………………………………...51 
    Introduction………………………………………………………………………………...51 
Results……………………………………………………………………………………...57 
Discussion………………………………………………………………………………............... 116 
Chapter Four: Conclusions…………………………………………………………………. 121 
Summary………………………………………………………………………………….121 
    Further development of NGS platforms…………………………………………………. 122 
   Challenging in cancer genome sequencing………………………………………………. 125 
Chapter Five: Materials and Methods……………………………………………………… 128 
Materials and Methods used in Chapter 2……………………………………………….. 128 
Cell culture and genomic DNA extraction……………………………………………. 128 
Library construction and sequencing…………………………………………………..128 
PET sequencing analysis……………………………………………………………….129 




        Comparison of libraries with different insert sizes…………………………………….. 133  
        Breakpoint confirmation by genomic PCR and Sanger sequencing……………………134 
        Copy number analysis……………………………………………………………………….  134         
        Fluorescence in situ hybridization (FISH)…………………………………………….  136  
        Reconstruction of genome structure by fusion point guided concatenation…………..  137 
Materials and Methods for Chapter 3……………………………………………………. 138 
Cell culture…………………………………………………………………………….. 138 
Clinic tumor samples………………………………………………………………….. 138 
Genomic DNA extraction……………………………………………………………... 139 
DNA-PET library cosntruction, sequencing and mapping……………………………. 139 
        Define dPET cluster count………………………………………………………………140 
        SNP and sequencing error simulation for mapping and clustering……………………. 145 
        Cross-genome comparison…………………………………………………………….. 146 
        Sequence features at the breakpoints of SVs…………………………………………... 147 
        Sequence similarity of breakpoint point pairs by blast……………………………….... 148 
Copy number of dPET clusters………………………………………………………... 149 



















All cancers are the result of changes that have occurred in the DNA sequence of the genomes of 
the cancer cells. We have learned much about these mutations and the abnormal genes that 
operate in human cancers in the last several decades. Now, we are moving to the new era in 
which it is possible to get the complete DNA sequence of large number of cancer genomes with 
the help of the next generation sequencing technologies. In this study, by comparing the 
characteristics of the large insert libraries (10-20 kb) with short insert (1 kb) libraries with the 
same sequencing depths and costs, we show that although short insert libraries bear an advantage 
in identifying small deletions they do not provide a significantly better breakpoint resolution. 
Large inserts are superior to short inserts in providing higher physical genome coverage and 
therefore achieve greater sensitivity for the identification of the different types of SVs, including 
copy number neutral and complex events. Applying the 10 kb DNA-PET technology to 15 cancer 
genomes, including both primary tumors and cancer cell lines, we show some important genomic 
characteristics in breast and gastric cancer genomes. With its versatile and powerful nature, the 
long span DNA-PET sequencing technology has a bright future ahead in studying the structures 
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Chapter One: Human cancer genome 
Introduction 
Cancer is accountable for one in eight deaths worldwide. It ranks as the second 
leading cause of death in economically developed countries (the first one is heart 
disease) and the third leading cause of death in developing countries (following heart 
diseases and diarrhoeal disease) (Garcia M. 2007). It encloses more than 100 different 
diseases with diverse risk factors and epidemiology which derive from most cell types 
and organs of the human body. Cancer is characterized by uncontrolled proliferation 
of cells which can invade beyond normal tissue boundaries and metastasize to distant 
organs. 
        (Stephens et al. 2012)In the late nineteenth and early twentieth century, David 
von Hansemann and Theodor Boveri examined dividing cancer cells under the 
microscope and observed the presence of bizarre chromosome aberrations. They 
speculated the numerical alterations on the chromosome level of a cell might 
contribute to tumourigenesis (Stratton et al. 2009). However, 50 years had been taken 
to support this speculation by identifying the first specific chromosomal abnormality, 
a marker chromosome called the Philadephia chromosome in cancer genomes of 
patients with chronic myelogenous leukaemia (CML) (Rowley. 1973). Subsequently, 
increased refined analyses of cancer chromosomes showed that cancer genomes are 
frequently altered in their gross chromosomal structures, and these changes lead to six 
essential alterations in cell physiology that collectively dictate malignant growth. 
These alterations include self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
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limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis (Hanahan et al. 2000).  
        Cancer development is based on two constituent processes, natural selection on 
the resultant phenotypic diversity and continuous acquisition of heritable genetic 
variation in individual cells by random mutations. The natural selection may remove 
cells which have acquired deleterious mutations or it may nourish cells which carry 
changes that confer the capability to proliferate and survive more effectively than 
other cells. Like all other cells in the human body, a cancer cell is also a direct 
descendant, through a lineage of mitotic cell divisions from the fertilized egg, from 
which the cancer patient developed and consequently carries a copy of its diploid 
genome. However, there are a set of acquired differences from its progenitor fertilized 
eggs in cancer cell genomes. These changes are accordingly termed somatic mutations 
to distinguish from germline mutations which are inherited from parents and 
transmitted to offspring. 
        Each somatic mutation in a cancer genome, no matter what kind of structural 
variations (SVs) it belongs to, may be classified by its consequences for cancer 
development. ‘Driver’ mutations have growth advantages on the cells which carry 
them and have been positively selected during the cancer revolution. They are 
inherent in the cancer genes. The other mutations are ‘passengers’ which do not have 
growth advantages and therefore do not have contributions to cancer development. 
Passenger mutations in cancer genomes are random somatic mutations without 
functional consequences. The most important goal of cancer genome research is to 
identify cancer genes which carry driver mutations and the key challenge therefore is 
to distinguish between driver and passenger mutations. The general strategy is to 
uncover a number of structural signatures related with mutations that are under 
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positive selection. For instance, driver mutations cluster in a subset of genes while 
passenger mutations are randomly distributed. Currently, at least 384 (2%) of the 
~22,000 protein-coding genes in the human genome are reported to have recurrent 
somatic mutations which contribute to cancer development (Santarius et al. 2010).  
Technologies for detecting cancer genomic SVs 
Somatic mutations in cancer comprise single nucleotide polymorphisms (SNPs) and 
SVs which can be further divided into microscopic variations (larger than 3 Mb) and 
submicroscopic variations. SVs include deletions, insertions, inversions, duplications, 
translocations and copy number variations (CNVs) (Feuk et al. 2006; Sharp et al. 
2006). All these SVs can be separated into two groups: balanced and unbalanced 
rearrangements. Based on the size and the pattern of SVs, different kinds of 
techniques can be chosen to interrogate the rearrangements in cancer genomes.  
1.1 Cytogenetic methods 
Since its first application in cancer research, cytogenetics has taken us from a state of 
nearly no knowledge of the chromosome changes in human cancer to a point at which 
an incredible body of information is available. The first era of cytogenetics began in 
1956 when the techniques were developed to accurately determine the number of 
chromosomes in a cell. However, early cytogenetics did not allow to distinguish most 
individual chromosome pairs from others of similar sizes and to define their general 
morphology. The chromosome basis of many diseases such as Down syndrome, 
Turner syndrome, Klinefelter syndrome had been established by these techniques; 
however, segmental gains or losses smaller than 25-50Mb in size were generally not 
detectable by these methods (Friedman. 2009). The second era of cytogentics started 
at the beginning of 1970s as the development of techniques for banding of human 
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chromosomes emerged. These techniques provide the ability to distinguish every 
chromosome pair unequivocally and identify deletions and duplications as small as 5-
10 Mb. The second era of cytogenetics led to the recognition of a large number of 
micro deletion/ micro duplication syndromes, including the Aniridia-Wilms tumor 
syndrome and those related with terminal deletion of chromosome 11q.  
        The introduction of fluorescence in situ hybridization (FISH) and subsequently 
stretched-fiber FISH marked the beginning of another new era of cytogenetics. By 
using fiber FISH, the resolution can be improved from the whole chromosomes in 
metaphase at ~5 Mb, or interphase nuclei at 50 kb to 2 Mb to the level of chromatin 
strands (5-500 kb) (Speicher et al. 2005). Although FISH is a robust test that can be 
used in a variety of diagnostic applications (Volpi et al. 2008), FISH only provides 
information about one or a few specific genomic regions which have been chosen for 
testing. Genome wide FISH based methods which include chromosome painting, 
Multiplex-FISH (M-FISH), spectral karyotyping technique (SKY) and cytogenetic 
comparative genomic hybridization are useful to clarify the nature of some 
chromosomal markers and rearrangements, but the resolution is still relatively low 
(Xu et al. 2003). 
1.2 Array based method.  
In the past decade, a revolutionary technology called array-comparative genomic 
hybridization (array-CGH) or more generally, array genomic hybridization (AGH) 
permit the identification of submicroscopic losses or gains anywhere in the genome. 
With thousands of locus specific probes immobilized onto microarrays, the patient 
and healthy reference genomic DNA can be compared by hybridization (Sharp et al. 
2006). Genomic clones (for instance, Bacterial Artificial Chromosome, BAC), 
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cDNAs, PCR products or oligonucleotides had been used as microarray probes. 
Among of them, BAC and oligonucleotide arrays are the most widely used probes. 
The advantage of AGH compared to conventional cytogenetic methods is the 
resolution as it can detect chromosomal gains or losses as small as 50-100kb 
anywhere in the genome. This is 100 times smaller than the resolution of the 
traditional cytogenetic method.  
        In the past few years, genome-wide genotyping arrays have been developed and 
applied in CNV detection. For instance, Affymetrix SNP Array 6.0 has 1.8 million 
genetic markers, representing more than 906,600 SNPs and 946,000 probes for CNVs. 
Meanwhile, Illumina Human1M BeadChip features more than 1.07 million SNP 
markers for CNV analysis covering 14,000 total CNV regions (Wu X M. 2009). 
Although array-based methods provide a genome-wide screening of variations, they 
are unable to detect copy number neutral variants, such as inversion or balanced 
translocation. They also cannot precisely describe the breakpoints and other fine 
details of the genomic rearrangements.  
1.3 PCR based methods 
Multiplex amplifiable probe hybridization (MAPH) and multiplex ligation-dependent 
probe amplification (MLPA) are two methods developed based on quantitative PCR. 
In 2000, MAPH was first described (Armour et al. 2000) while two years later, 
MLPA was developed (Schouten et al. 2002). Both technologies rely on comparative 
quantification of specifically bound probes that are amplified by PCR with universal 
primers. In the MAPH technique, low amount genomic DNA (1µg) without any pre-
amplification is fixed onto a membrane and hybridized with a set of probes 
corresponding to the target sequences to be detected. All probes are flanked by the 
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same sequence. After removing unbound probes by stringent wash, the remaining 
specifically bound probes are then stripped from the membrane and amplified by the 
universal primer pair. Since each amplified probe has a different length, the PCR 
products can be separated by gel electrophoresis and the amount of amplified product 
is directly proportional to the copy number in the genomic DNA (Sellner et al. 2004). 
QuadMAPH is a newly developed method which allows the user a four-fold increase 
in the number of loci tested simultaneously without the expense of genome-wide 
approaches (Tyson et al. 2009). Duet to its more limited DNA consumption (50ng per 
assay) and single-tube assay set up, MLPA has become widely used compared to 
MAPH. In the MLPA technique, each target has two probes which hybridize 
adjacently to each other and all probe pairs are flanked by universal primers. After 
hybridization, the two parts of the probe pair are joined together by a ligation reaction, 
and the number of ligated products is proportional to the target copy number. 
Currently, MAPH and MLPA fill an important gap in the assay methodology between 
genome-wide CGH platforms and single locus low-throughput methods. The most 
important advantages of these two methods are relative simplicity, speed, cost-
effectiveness and high accuracy in detecting small genomic changes; however, the 
limited complexity due to gel-based detection is a major drawback (Kozlowski et al. 
2008).  
1.4 Sequence based methods  
The complete sequence of the human genome (International Human Genome 
Sequencing Consortium, 2004) provides another approach to detect SVs. In 2005, 
Tuzun et al. sequenced a high density fosmid library by conventional sequencing 
technology (ABI3100) and mapped 589,275 paired end sequences against the human 
reference genome assembly (Tuzun et al. 2005). Around three hundred sites of SVs 
 7 
had been identified including 139 insertions, 102 deletions and 56 inversion 
breakpoints. This method can simultaneously sequence and precisely characterize any 
structural variation based on a clone library. It allows the detection of balanced 
rearrangements like inversion. However, due to the insert size (~40 kb) of the fosmid 
vector, the smallest size of detectable SVs is larger than 8 kb in length. And the high 
cost of the conventional sequence technology also prohibits this method to be widely 
used for genome wide SVs detection. 
        We just experience the next technological revolution in biological science, the 
advent of relatively cost effective, massively parallel DNA sequencing technologies. 
Over the last two years, it has become possible to resequence the entire human 
genomes at single nucleotide resolution. It is expected that in the next 3-4 years, a 
single human genome can be sequenced within days for around 1,000 dollars 
(Aparicio et al. 2010).  
        The most limited step in conventional Sanger-based sequencing of DNA 
comes from separating randomly terminated DNA polymers by gel electrophoresis. 
Next generation sequencing (NGS) devices bypassed this limitation by physically 
arraying DNA molecules on solid surfaces and determining the DNA sequence in situ. 
The first generation approaches, for example Roche 454 sequencing (Margulies et al. 
2005), currently achieve 200-400 bp reads over hundreds of thousands of templates. 
The current generation of machines, such as Illumina  HiSeq devices (Bentley et al. 
2008), ABI SOLiD machines (McKernan et al. 2009) and Complete Genomics 
Amplified DNA nanoarray platform (Drmanac et al. 2010) are capable of sequencing 
tens of millions of individual templates in parallel with 100 bp read length. Paired-end 
sequencing (PES) (Holt et al. 2008), paired- end mapping (PEM) (Korbel et al. 2007) 
or Paired-end tag (PET) (Chen et al. 2008) are the methods developed based on the 
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NGS. Albeit different nomenclature, the underlying principle is the same: the 
extraction of short tag sequence information from the two ends of long DNA 
fragments, the pairing of the two tags, and the mapping of the paired tag sequences to 
reference genomes for demarcating the boundaries of the target DNA fragments in the 
genome landscape (Fullwood et al. 2009). PET can be used on RNA (RAN-PET) for 
transcripton analysis (Morin et al. 2008), on DNA (DNA-PET) for the identification 
of genome SV and can aid genome sequence assembly (Korbel et al. 2007). Further, 
PET can be applied on manipulated DNA fragments such as ChIP-enriched DNA 
(ChIP-PET) for mapping of transcription factor binding sites (TFBSs) (Wei et al. 
2006) and on proximity-ligated DNA for chromatin interaction analyses (ChIA-PET) 
(Fullwood et al. 2009).  
        The first genomic sequence of a cancer was described by Ley et al (Ley et al. 
2008) and Illumina GA technology was used to attain a nearly 33-fold coverage of an 
acute myeloid leukaemia (AML) patient genome. At the same time, a 14-fold genome 
coverage of a normal skin sample from the same patient was obtained as a germ line 
control. The genome of this patient is cytogenetically normal and diploid, which 
represent a simpler case than the genomes of cytogenetically complex and much more 
common carcinomas. However, the analysis provides an informative snapshot of what 
we can expect from cancer genome resequencing. A total of ten non-synonymous 
somatic mutations were identified in the patient’s genome. Two are well known 
AML-associated mutations and both of them are common (25-30%) in AML tumors. 
The other eight are new described and of unknown function or relevance to the 
tumorigenic process. This study establishes whole-genome sequencing as an unbiased 
method for discovering cancer-initiating mutations in previously unidentified genes 
that may respond to target therapies. 
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        The same strategy had been applied to another AML patient and a total of 64 
somatic mutations had been identified (Mardis et al. 2009). Four mutations occurred 
in at least one additional AML tumor sample of 188 additional AML samples that 
were tested. Mutations in NRAS and NPM1 had been identified before but the other 
two mutations were new. One mutation in the gene IDHI was present in 15 of 187 
additional AML genomes and was strongly associated with normal cytogenetic status. 
The other mutation located in a non-genic evolutionarily conserved region, is pointing 
to the importance of the development of a strategy for informative analyses of non-
protein encoding alterations with potential regulatory functions. Understanding the 
potential regulatory effects of these alterations will be of key importance in 
understanding the molecular mechanism of cancer. 
        The advances in NGS also can be used to characterize all somatic mutations 
that occur during the development and progression of individual cancers. The genome 
of an estrogen-receptor-α-positive metastatic lobular breast primary tumor and a 
metastasis collected from the same patient 9 years later had been sequenced and 
compared (Shah et al. 2009). The results provided insight into the evolution of the 
cancer genome associated with disease progression. Of all the 32 somatic mutations 
detected in the metastasis, only 11 could be detected in the primary tumor. Five of the 
11 mutations were prevalent in the DNA of the primary tumor and the others were 
present at low frequencies (1-13%). The authors noted that the prevalence of new 
mutations in metastases could reflect those associated naturally with tumor 
progression, and those induced by treatments such as radiation therapy. Another 
significant feature of this study is the integration of genome and transcriptome 
analysis. The authors examined how the transfer of information from the nuclear 
genome to proteins was modified by alternative splicing, biased allelic expression and 
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RNA editing. Several hundred putative RNA-editing events were observed that would 
potentially result in non-synonymous protein changes not coded directly by the gene. 
Two genes, COG3 and SRP9, showed confirmed high frequency non-synonymous 
transcript editing, resulting in variant protein sequences. More interesting, the ADAR 
enzyme, one of the principal RNA-editing enzymes, was the only editing enzyme 
expressed at a high level. These observations highlight the importance of integrating 
RNA-seq data with tumor genomes, and that the quantitative and digital aspects of 
NGS can together be applied to understand gene activation/inactivation.  
        In the same year, Pleasance and colleagues sequenced two human cancer cell 
lines, NCI-H209 which is an immortal cell line derived from a patient with small-cell 
lung cancer (SCLC) and COLO-829 derived from a metastasis of a malignant 
melanoma patient (Pleasance et al. 2010a; Pleasance et al. 2010b). In the first case, 
total 22,910 somatic substitutions were identified, including 134 in coding exons. 
However, most of the mutations in coding and promoter regions of the NCI-H209 
genome are passenger events, without selective advantages to the cells. At least two 
separate DNA repair pathways have been uncovered for protection of the NCI-H209 
genome, and the two pathways operated with differing efficacy across six classes of 
mutation, which implies that the lesions have distinct physicochemical effects on 
DNA structure, and could be variable recognized and excised by the genome 
surveillance machinery. A 39 kb tandem duplication (TD) was found in CHD7, 
predicted to lead an inframe duplication of exon 3-8 and another two SCLC cell lines 
carried a PVT1-CHD7 fusion gene within the MYC amplification. As a chromatin 
remodeler, CHD7 can promote enhancer-mediated transcription through association 
with histone H3K4 methylation. Histone modifiers have been implicated as cancer 
genes and the recurrent of CHD7 in SCLC will extend this theme. 
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        In the second case, a malignant melanoma and a lymphoblstoid cell line from 
the same person had been sequenced and provided the first comprehensive catalogue 
of somatic mutations from an individual cancer. Most somatic base substitutions in 
COLO-829 were C>T/G>A transitions and this indicated that COLO-829 were 
attributable to ultraviolet-induced DNA damage.  The catalog showed traces of the 
multiple levels of selective application of DNA repair: targeting transcribed rather 
than untranscribed, exons rather than introns, transcribed DNA strands rather than 
non-transcribed strands, and 5’ rather than 3’ ends of genes.  
        Tumor-specific chromosome rearrangements have the potential to serve as 
highly sensitive biomarkers for tumor detection, such as those involving the BCR-ABL 
oncogene (Hughes et al. 2006). Rearrangement-associated biomarkers also offer a 
reliable measure that would be useful for monitoring tumor response to specific 
therapies, detecting residual disease after surgery and long-term clinical management. 
However, recurrent structural mutations do not generally occur in most solid tumors. 
A method, called personalized analysis of rearranged ends (PARE) had been 
developed to identify translocations in solid tumors (Leary et al. 2010). Four 
colorectal and two breast cancers had been sequenced by massively parallel 
sequencing and revealed an average of nine rearranged sequences (range, 4 to 15) per 
tumor. PCR with primers spanning the breakpoints was able to detect mutant DNA 
molecules present at a level lower than 0.001% and identified mutated circulating 
DNA in patient plasma samples. These results highlight the sensitivity and specificity 
of the approach and suggest broad clinical utility of the PARE method. However, the 
approach has some limitations related to the loss of some rearranged sequences during 
tumor progression and the current high sequence cost.  
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        Although the cost of genomic information has fallen steeply, the clinical 
translation of genetic risk estimates is not straight forward. Since the present 
analytical methods are not sufficient to make genetic data accessible in a clinical 
context, the clinical usefulness of these data for individual patients has not been 
formally assessed. A pioneer study undertook an integrated analysis of a complete 
human genome in a clinical context (Ashley et al. 2010). The genome of a patient 
with a family history of vascular disease and early sudden death had been sequenced, 
and 2.6 million SNPs and 752 CNVs showed increased genetic risk for myocardial 
infarction, type 2 diabetes and some cancers. Rare variations were found in three 
genes which are clinically associated with sudden cardiac death--- TMEM43, DSP and 
MYBP3. A variant in LPA was consistent with a family history of coronary artery 
disease. A heterozygous null mutation in CYP2C19 suggested possible clopidogrel 
resistance and variants in CYP4F2 and VKORC1 might have a low initial dosing 
requirement for warfarin. The patient had several variants that are associated with 
good response to statins and one variant suggested that he might need a raised dose to 
achieve a good response.  
        This study provided an approach to comprehensively analyze a human genome 
in a defined clinical context. The authors assessed whole genome genetic risk, 
focusing on variants in genes that are associated with Mendelian diseases, novel and 
rare variants across the genome, and variants of pharmacogenomic importance. 
Additionally, this study developed an approach to interrogate disease risk across 
several common polymorphisms. However, there are still important limitations to 
comprehensively integrate genetic information into clinical care. Such as, a 
comprehensive database of rare mutations is needed and a continually updated 
pipeline is necessary. As whole genome sequencing becomes increasingly widespread, 
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availability of genomic information will no longer be the limiting factor in the 
application of genetics to clinical medicine. Development of methods integrating 
genetic and clinical data will assist clinical decision making and represent a large step 
towards individualized medicine. The transition to a new era of genome-informed 
medical care will need a team approach incorporating medical and genetics 
professionals, ethicists and health-care delivery organizations.  
        Two recent studies demonstrated the power that these whole genome sequence 
data hold for patients with a diagnosis of cancer. In the first report, Link and 
colleagues (Link et al. 2011) performed whole genome sequencing on the skin and 
bone marrow DNA of a patient with early-onset breast and ovarian cancer (negative 
for BRCA1 and BRCA2 mutations) and therapy-related acute myeloid leukemia (t-
AML). The result revealed a novel and heterozygous 3 kb deletion removing three 
exons (7-9) of TP53 in the normal skin DNA, which was homozygous deleted in the 
leukemia DNA due to uniparental disomy. Without whole-genome sequencing, this 
novel mutation in TP53 would not have been discovered. Although the life of the 
patient could not be saved by the discovery, the implications for her children who 
may have inherited this mutation are immediate.  
        In the second study, Welch and colleagues (Welch et al. 2011) sequenced the 
DNA extracted from the leukemic bone marrow and a skin biopsy from a 39-year-old 
woman whose clinical presentation was consistent with acute promyelocytic leukemia, 
however, cytogenetic analysis revealed a different subtype associated with a poor 
prognosis. A novel insertional translocation on chr17 which created a pathogenic 
fusion gene PML-RARA was identified and this type of genetic event could not have 
been identified by traditional cytogenetic techniques. The whole genome sequencing 
results led to a change in AML therapy including giving the patient retinoic acid 
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which significantly improves the overall prognosis of patients with AML. Bone 
marrow transplantation is no longer considered in first remission. The remarkable 
achievement of this study is to generate comprehensive genomic data in a time frame 
that is clinically relevant for a patient. 
        With the fast development of new DNA sequencing technologies which are 
reducing the cost and accelerating our ability to study the complete genomic 
landscape, the somatic genetic changes that underline the initiation and progression of 
human cancer are rapidly becoming known. Cataloguing these changes and the 
frequency at which they occur in specific tumors and tumor subtypes is the first 
critical step on the path to understand what drives the oncogenic process. The 
complexity of the cancer genomes has been confirmed by the results from many 
cancer genome sequencing efforts to date and these achievements also solidify the 
concept that no two tumors are created equally even if they belong to the same 
histological subtype. Another impetus for studies of somatic genome alterations is the 
potential for therapies targeted against the products of these alterations. For example, 
treatment with the inhibitors of the epidermal growth factor receptor kinase (EGFR), 
gefitinib and erlotinib, leads to a significant survival benefit in patients with lung 
cancer who carry EGFR mutations, but no benefit in patients who carry wild-type 
EGFR. Therefore, comprehensive genome-based diagnosis of cancer is becoming 






Chapter Two: Long Span (DNA-PET) Sequencing Strategy for the Interrogation 
of Cancer Genomic Structural Variations  
Introduction 
The relatively short reads (~35-450bps) generated by current next generation high –
throughput DNA sequencing technologies cannot allow us to sequence a genome in 
its entirety using de novo assembly, which means construct the genome sequence 
based solely on the sequencing reads without any other prior knowledge. The 
determination of a new genome sequence relative to a reference genome is often 
referred to as resquencing. In each resequencing project, there are five parameters that 
can be used (1) SNPs, (2) small indels (2-1000 bp), (3) large structural variations 
(>1000 bps), (4) new sequences which are not present in the reference genomes and 
(5) Genotype/haplotype information. 
        In general, the identification of SNPs and small indels is relatively straight 
forward although low sequence complexity is a confounding factor. However, the 
identification of large SVs is a routine procedure yet, because the extent of altered 
sequences at the SVs breakpoint and the presence of repetitive sequences can make 
SV detection difficult. The sequence reads cannot be unambiguously mapped the 
reference when the SVs reside in repetitive regions of the genome. Human DNA 
sequences could be broadly classified as four kinds of repeats: 1) segmental 
duplications also known as low copy repeats (LCR) (> 1 kb in length with 90% of 
sequence identity between copies), which are induced by recombinational processes 
and comprise about 5% of the human genome; the majority is located in the 
pericentromeric and subtelomeric regions.  LCRs longer than 10kb and of over ~97% 
sequence identity can mediate or stimulate CNV formation by creating local genomic 
instability. LCRs have been shown to stimulate and/or mediate constitutional (i.e., 
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inherited; both recurrent and nonrecurrent) evolutionary, and somatic genomic 
rearrangement (Gu et al. 2008); 2) simple sequence repeats (1-13 nucleotides) that 
arose by DNA polymerase slippage during replication; simple sequence repeats make 
up ~3% of the human genome; 3) transposable elements also known as interspersed 
repeats (few kilobases) which comprise the largest component of mammalian 
genomes (Babushok, D.V, 2006); 4) tandem repeats of the centromeric and telomeric 
regions which are often excluded from genome assemblies. In addition, SVs are often 
complex, with the occurrence of multiple events in close proximity, so that the events 
cannot be correctly detected by short reads. Although SVs account for a large 
proportion of base pairs which are affected by variation in the genome (Kidd et al. 
2008; Korbel et al. 2007), it is likely that a substantial number of SVs are missed in 
most genome sequencing projects (Table 2.1) because of current limitations in the 
extraction of SV information from short read genome sequencing data. 
        The PET technologies differ in the length of the DNA fragments that are 
sequenced from both ends. Currently, the commonly used fragment lengths for 
paired-end sequencing range from 200 bp to 3 kb. In theory, small insert size (sub-
kilo base) has the advantages of a tight size range of DNA fragments and thereby a 
greater sensitivity for the detection of small insertions and deletions. In contrast, large 
insert size (one kilo base to tens of kilo bases) has the advantage of higher genomic 
physical coverage with the drawback of less precise localization of breakpoint regions. 
It is expected that a combination of paired-end reads from different length fragments 
will provide optimal SV detections. To address this question, our group developed a 
robust procedure to construct larger insert size libraries (10-20 kb) and we used three 
well established cancer cell lines including the breast cancer cell line MCF-7, the 
colon cancer cell line HCT116 and the chronic myelogenous leukaemia (CML) cell 
 17
line K562 as test genomes. We compared the characteristics of the large insert size 
libraries (10 kb and 20 kb) with short insert size (1 kb) libraries at the same 
sequencing depths and costs. Although short insert size libraries bear an advantage in 
identifying small deletions, they do not provide a significantly better breakpoint 
resolution. Large insert size libraries are superior to short insert size libraries in 
providing higher physical genome coverage and therefore achieve greater sensitivity 
for the identification of the different types of SVs, including copy number neutral and 
complex events. Further, large insert size libraries allow the identification of SVs 
within repetitive sequences which cannot be spanned by short inserts. 
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Table 2.1: Individual genomes which have been sequenced by PET technology 
Project Technology SVs Fragment size Reference 
African, European Illumina 5,740 200bp Bentley 2008 
Lung cancer genome Illumina 409 500bp&200bp Campbell et al. 2008 
AML genome  Illumina 726 (1-30bp) 150-200bp Ley et al. 2008 
AML genome  Illumina Limited 95bp to 298bp Mardis et al. 2009 
24 human  breast cancer Illumina 2,166 500bp Stephens et al. 2009 
HapMap sample SOLiD 5500 (unknown definition) 1.4kb McKernan et al. 2009 
Melanoma genome Illumina 51 200bp & 400bp Pleasance et al. 2010a 
Lung cancer genome SOLiD 392 500-600bp & 3-4kb Pleasance et al. 2010b 
Giloma cell line SOLiD 1314 1.4kb Clark et al. 2010 
A patient Heliscope  752 CNVs  100-500bp Ashley, 2010 
Four colorectal and two breast 
cancers 
SOLiD 54 1.4kb Leary et al. 2010 
A child with bilateral, young-onset 
Wilms tumor 
Illumina 1 3kb Slade et al. 2010 
A Japanese individual Illumina 5,488 200bp Fujimoto et al. 2010 
A basal like breast cancer Illumina 302 200bp Li Ding et al. 2010 
A lung cancer tumor Complete Genomics 344 200-400bp Lee et al. 2010 
13 pancreas cancer Illumina 558 400-500bp Campbell et al. 2010 
A hepatocellular carcinoma Illumina 33 250bp Totoki et al. 2011 
Seven primary human prostate 
cancers 
Illumina 755 400bp Berger et al. 2011 
CML and bone cancer Illumina 371 400-500bp Stephens et al. 2011 






DNA-PET library construction and sequencing 
We randomly sheared the genomic DNA from MCF-7, HCT116, and K562 to the desired size 
range and gel-purified a narrowed range of 1 kb, 10 kb, and 20 kb DNA fragments, respectively. 
The DNA fragments were subjected to DNA-PET library construction and sequencing to 
generate PET sequences with each tag of 25 bp tag length (details in Materials and Methods). 
The PET sequences (2 x 25 bp) were mapped to the reference genome (NCBI build 36) with 
SOLiD System Analysis Pipeline Tool, Corona Lite, allowing 2 color-code mismatches (Figure 
2.1). In total, we generated seven genomic DNA-PET datasets, two each for MCF-7 and 
HCT116 (1 kb and 10 kb) and three for K562 (1 kb, 10 kb and 20 kb, Table 2.2). 









Concordant PET  tag density














                          Figure 2.1.  DNA-PET library construction, sequencing and mapping.  
(A) The genomic DNA was randomly sheared to different size range. (B) The very narrow region DNA 
fragments were obtained after size selection. (C) The purified DNA fragments were circularized, EcoP15I 
digested, sequencing adaptor ligated and finally sequenced by SOLiD sequencer. (D) PET mapping span 
distribution in 1kb (blue), 10kb (red) and 20kb (green) libraries. Based on the mapping pattern, PET can 
be distinguished as concordant PET and discordant PET.  
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        To get comparable non-redundant PET numbers among different insert size libraries of the 
same genome, we randomly selected a subset of original MCF-7 and HCT116 10 kb libraries 
(Hillmer et al. 2011) resulting in approximately 20 million non-redundant (NR) PET sequences 
for all MCF-7 and HCT116 libraries. The 18.4 million non-redundant and uniquely-mapped PET 
sequences of the MCF-7 10 kb library resulted in approximately 69-fold physical (fragment) 
coverage of the human genome. Of these PET sequences, 88% (16.3 million) were mapped 
concordantly to the reference genome as concordant PETs (cPETs) (5’ and 3’ tags of a PET 
mapped on the same chromosome, same strand in 5’3’ orientation and within the expected 
insert size). The MCF-7 10 kb cPETs were mapped within the range of 8,099 bp to 16,217 bp 
and with a peak of the insert size distribution at 11,273 bp. This proportion of PETs reflected the 
agreement of the genome architecture between MCF-7 and the reference genome. In contrast, 
11.6% (2.1 million) of the uniquely-mapped PETs were mapped as discordant PETs (dPETs) (5’ 
and 3’ tags of a PET mapped too far away or too close to each other, or mapped in reversed order 
as 3’5’, or mapped on different strands or different chromosomes). These dPETs were 
indicative of potentially rearranged genomic regions crossing the breakage/fusion junction points 
where the MCF-7 genome is different from the reference genome. In the MCF-7 1 kb dataset, 
96% (17,598,541 of 18,335,127) NR PET were concordantly mapped to the reference genome 
and 4% (736,586) were discordant. The lower proportion of dPETs in the 1 kb library is due to 
the low number of short span PET constructs which comprise the largest proportion of dPETs for 
10 kb libraries (Hillmer et al. 2011). As expected, the physical coverage of the MCF-7 1 kb 
library was considerably lower (8-fold) compared to the 10 kb library (69-fold) with the same 
number of NR PETs (18 million). In K562, the comparable number of NR PETs (~ 40 million) 
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Table 2.2. DNA-PET library statistics 
















Total Tags 270,334,239 233,715,372 234,045,521 357,273,623 311,788,203 564,115,773 410,069,683 
Mappable Tags 73,484,523 97,200,820 106,838,016 212,486,672 183,080,988 335,776,419 246,267,355 
PET 20,899,040 22,856,160 28,389,915 53,175,650 85,086,071 133,675,193 83,261,984 
NR PET 1) 18,335,127 18,432,387 20,613,096 20,610,717 41,996,278 44,065,447 38,393,242 
Redundancy 1.14 1.24 1.38 2.58 2.03 3.03 2.17 
Span Range 1,155-1,514 8,099-16,217 1,186-1,574 7,200-11,780 880-1,320 6,846-10,248 15,590-33,140 
Median 1,347 11,273 1,367 8,514 1,100 8,303 21,700 
Coverage 8.2 69.3 9.4 58.5 15.4 122.0 277.7 
cPET 2) 17,598,541 16,292,711 18,919,833 17,938,263 39,818,591 40,261,305 35,246,258 
cPET % 3) 96.0% 88.4% 91.8% 87.0% 94.8% 91.4% 91.8% 
dPET 4) 736,586 2,139,676 1,693,263 2,672,454 2,177,687 3,804,142 3,146,984 
dPET % 5) 4.0% 11.6% 8.2% 13.0% 5.2% 8.6% 8.2% 
Singleton 728,445 2,119,094 1,688,547 2,661,375 2,157,688 3,771,859 3,103,814 
Singleton % 6) 98.9% 99.0% 99.7% 99.6% 99.1% 99.2% 98.6% 
dPET  cluster (≥2) 1,689 1,663 997 1,422 4,432 3,225 7,636 
dPET 7) 8,141 20,582 4,716 11,079 19,999 32,283 43,170 
% 8) 1.1% 1.0% 0.3% 0.4% 0.9% 0.8% 1.4% 
1)
 non-redundant PET 
2)
 concordant PET 
3)
 Proportion of concordant PET to NR PET 
4)
 discordant PET 
5)
 Proportion of discordant PET to NR PET 
6)
 Proportion of singleton to dPET 
7)
 dPET which belong to the cluster size ≥2 
8)





Large structural variations identified by different insert size libraries  
Each of the dPETs could potentially map over a breakage/fusion point. However, it is inevitable 
that spurious dPET mappings would arise due to chimeric ligation during the construction of 
DNA-PET libraries or incorrect tag mapping. To reduce such random noise, we used the PET 
mapping overlap scheme (clustering, detail in Materials and Methods) to discard all the singleton 
and cluster size 2 dPETs and considered only the dPET clusters with multiple overlapping PETs 
(≥3) as true signals for further analysis of genome rearrangements (Table 2.3; Figure. 2.2).  
Table 2.3. dPET cluster statistics 
Library  Total Singleton Cluster 2 Cluster 3 Cluster 4 Cluster 5 cluster >5 
MCF7 1kb 736,586 728,445 1,330 1,176 928 625 4,082 
% 100% 98.89% 0.18% 0.16% 0.13% 0.09% 0.55% 
MCF7 10kb 2,139,676 2,119,094 1,268 459 388 385 18,082 
% 100% 99.04% 0.06% 0.02% 0.02% 0.02% 0.85% 
HCT116 1kb 1,693,263 1,688,547 850 555 488 385 2,438 
% 100% 99.72% 0.05% 0.03% 0.03% 0.02% 0.14% 
HCT116 10kb 2,672,454 2,661,375 1,330 462 320 285 8,682 
% 100% 99.59% 0.05% 0.02% 0.01% 0.01% 0.32% 
K562 1kb 2,177,687 2,157,688 5,430 1,560 1,236 1,175 10,598 
% 100% 99.08% 0.25% 0.07% 0.06% 0.05% 0.49% 
K562 10kb 3,804,142 3,771,859 3,682 894 636 495 26,576 
% 100% 99.15% 0.10% 0.02% 0.02% 0.01% 0.70% 
K562 20kb 3,146,984 3,103,814 10,888 3,048 1,504 820 26,910 






















MCF7 1kb MCF7 10kb HCT116 1kb HCT116 10kb
K562 1kb K562 10kb K562 20kb
 
Figure 2.2. dPET cluster size distribution. 
The number of dPET clusters (y-axis) is shown for the individual cluster sizes (x-axis). Red vertical line 
represents the cutoff for dPET clusters regarded as reliable breakpoint pairs (size three and higher). 
           
        The large insert size and high sequencing depth of the libraries allowed for the identification 
of different types of SVs, including deletions (the 5’ mapping anchor region was far apart from 
the 3’ mapping anchor region), tandem duplications (the mapping order was 3’ to 5’ instead of 
the normal 5’ to 3’), unpaired inversions (the mapping orientation was reversed, on different 
strand), isolated translocations (the 5’ and 3’ anchors mapped to different chromosomes). Two 
closely positioned dPET clusters could be used to deduce the SVs with two rearrangement points 
such as inversions, insertions, and balanced translocations (details in Materials and Methods). In 
addition and in contrast to previous studies, eight different sub-types of insertions were 
characterized in this study. The eight sub-types of insertions included different combinations of 
intra or inter-chromosomal, direct or inverted, forward or backward insertions (Figure 2.3).  
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Figure 2.3. SVs identification based on the mapping pattern of dPET clusters. 
The dark red and pink arrows represent the 5’ and 3’ anchor region of the dPET cluster. Black, 
white and gray horizontal lines represent chromosome segments. The sub-type of insertion as 
follows: (1) Intra chromosome direct forward insertion. (2) Intra chromosome direct backward 
insertion. (3) Intra chromosome inverted forward insertion. (4) Intra chromosome inverted 
backward insertion. (5) Deletion plus intra chromosome direct forward insertion. (6) Deletion 
plus intra chromosome inverted forward insertion. (7) Inter chromosome direct insertion. (8) 
Inter chromosome inverted insertion. 
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        A high count for a dPET cluster (large number of dPETs spanning the same breakage/fusion 
point) gives high confidence for the rearrangement point and may also reflects the copy number 
of the breakage/fusion point. The highest dPET cluster count in the MCF-7 10kb library was 766 
and only 91 in the corresponding 1 kb library. We observed similar drops in cluster count for 
HCT116 (148 in the 10 kb library and 63 in the 1 kb library) and K562 (2,106 for the 20 kb 
library, 692 for the 10 kb library and 127 for the 1 kb library, respectively). Using cluster count 3 
as cut off, the numbers of identified SVs in the 10 kb library of MCF-7, HC116, and K562 were 
899, 654, and 1,570 (Table 2.4). The total number of SVs identified in the 1 kb libraries of each 
genome was comparable to the number of SVs found in the 10 kb libraries; however, the 
composition of the SV types was different. In the 1 kb libraries, the vast majority of SVs was 
deletion (79% in MCF-7, 80% in HCT116, and 78% in K562); whereas in the 10 kb libraries, the 
percentage of deletions was much lower (33% in MCF-7, 59% in HCT116, and 38% in K562). 
In contrast, the number of inversions and insertions identified in 1 kb libraries was much lower 






















          Intra chr  Inter chr        
MCF7  1kb 739 51 1 1 4 46 93 0 
 10kb   300 226 30 13 23 126 180 1 
HCT116  1kb  415 32 4 1 4 29 35 0 
 10kb  385 86 33 13 13 55 69 0 
K562  1kb  1,252 110 14 5 9 85 123 0 
 10kb  590 203 35 39 16 205 482 0 
 20kb 
980 (3) 
106 47 19 15 104 162 0 
  211 (5)* 
                       *The large span window of this library created many artificial deletion clusters; hence we increased the cluster size cut off from 3 to 5 
                          to reduce the number of false positive calls. 
 
Table 2.5. Sub-types of insertions in individual libraries 
Sub-type of insertion MCF7 HCT116 K562 
  1kb 10kb 1kb 10kb 1kb 10kb 20kb 
Intra chromosome forward direct insertion 0 4 1 7 3 12 2 
Intra chromosome backward direct insertion 0 0 0 1 2 7 8 
Intra chromosome forward inverted insertion 1 5 0 2 0 10 2 
Intra chromosome backward inverted insertion 0 3 0 2 0 8 6 
Deletion plus intra chromosome forward direct insertion 0 0 0 0 0 1 0 
Deletion plus intra chromosome forward inverted insertion 0 1 0 1 0 1 1 
Inter chromosome direct insertion 0 8 2 8 4 10 9 
Inter chromosome inverted insertion 4 15 2 5 5 6 6 
Total 5 36 5 26 14 55 34 
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Classify isolated and complex SVs in each library 
In some amplified loci of cancer genomes, due to the complicated genomic architecture, a 
large number of dPET clusters were connected to form complex rearrangement units. In these 
units, it might be misleading to assign a particular SV type to a dPET cluster e.g. if the 
breakpoints of a tandem duplication are surrounded by deletions and/or translocations, the 
rearrangement might not be interpreted as a tandem duplication. Therefore, a breakpoint 
based interconnection network was established to separate breakpoints in complex regions 
from isolated and less complex SVs. (Figure 2.4 and details in Materials and Methods). Non-
complex deletions, tandem duplications, unpaired inversions, and isolated translocations 
involve only one cluster, which was reflected by a supercluster count 1. Superclusters with 
count 2 comprised inversions, insertions and balanced translocations which involved two 
dPET clusters. Deletions or tandem duplications plus insertions or inversions were the major 
source of superclusters with count 3. We observed a significant number of SVs that were 
connected by multiple dPET clusters to form complex rearrangement units in which the exact 
architecture was complicated by overlapping of multiple SV events. Therefore, we classified 
supercluster count 4 or more connected SVs as complex. The supercluster analysis result 
showed that 1 kb library contained more isolated SV events than 10 kb libraries and the major 
contribution came from deletions (Figure 2.5). MCF-7 had the most complicated 
rearrangement unit and higher supercluster counts than HCT116 and K562. The largest 
rearrangement unit in the MCF-7 10 kb library involved 212 dPET clusters, of which 210 
were located in the amplified regions on chromosomes 1, 3, 17, and 20. The highest 
supercluster count of the 10 kb library in K562 and HCT116 was 115 and 41, respectively. 
The lower highest supercluster count in HCT116 indicated less rearrangement of this genome 





















Deletion + inverted insertion at other location
Deletion + inverted insertion of a 
smaller fragment




Figure 2.4. Supercluster definition and categories. 
(A) Connectivity of breakpoints. An interconnection network was established by grouping together 
dPET clusters (to superclusters) which have at least one anchor region within 10kb of each other. This 
may result in an indirect connection of cluster D and C. 5’ anchor regions are indicated in dark red, 3’ 




Figure 2.5. Supercluster statistics in individual library. 
(A-G) Distribution of degrees of connectivity represented by superclusters in each library. Numbers of clusters (y-axis) for each supercluster 
count (number of interconnected clusters, x-axis) is shown. (H) Color code of each kind of SV. 
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Comparison of isolated SVs from 1 kb, 10 kb and 20 kb DNA-PET libraries 
 To determine the sensitivity of different insert sizes to identify SVs, we compared SVs from 
different insert size libraries of each genome. We excluded complex SVs from this analysis but 
included clusters of size 2 for SVs which matched an SV in another library. For 10 kb and 20 kb 
libraries specific SVs, we increased cluster count cut off from 3 to 6 to increase the confidence. 
The result showed that 1 kb libraries could identify more deletions than 10 kb libraries. Such 1 
kb library-specific deletions were usually smaller than 5 kb. The span of most deletions detected 
by 10 kb libraries ranged between 5 kb and 500 kb (Figures 2.6.A).   
        Inversions are prone to map to segmental duplications (Stefansson et al. 2005). The 
ambiguous mapping for sequence tags of segmental duplications results in the exclusion of such 
tags in most pipelines and the inability to identify breakage/fusion points in these regions. Small 
insert libraries such as 1 kb libraries are less likely to span such regions of ambiguous mapping 
and are expected to have lower detection rates for inversions. The lower physical coverage of 1 
kb libraries, as compared to 10 kb libraries further limits their ability in identifying inversions. 
The MCF-7 1 kb library resulted in only 1 inversion with a cluster size ≥3 (Table 2.4). However, 
the comparison with the 30 inversions identified by the 10 kb library indicated that 3 inversions 
matched with at least one low confidence cluster of size 2 in the 1 kb library. Similarly, we 
identified 34 inversions by the 10 kb library in HCT116 and found evidence by low confidence 
clusters for only 4 inversions by the respective 1 kb library. Compared to 1 kb libraries of MCF-
7 and HCT116, the higher total PET number of the K562 1 kb library resulted in a higher 
physical coverage and the identification of more inversions. In K562, there were two 1 kb library 
specific inversions with a span of 509 bp and 836 bp, respectively. The 10 kb library data of 
K562 contained one of the two clusters which identify an inversion.  
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       The difference in the detection rate of insertions between 1 kb and 10 kb libraries was 
comparable to inversions. There was no 1 kb library-specific insertion in MCF-7. In HCT116 
and K562, two and one 1 kb library-specific insertions were identified, respectively, and all were 
smaller than 1 kb. Of these three small insertions, the respective 10 kb libraries identified one of 
the two breakage/fusion points. In summary, compared to 1 kb libraries,  
10 kb libraries had a higher sensitivity in identifying more and large span SVs. All the SVs 
which were specific to 1 kb libraries and which were missed by 10 kb libraries had either a low 







Figure 2.6. Comparison of number and span distribution of specific SVs identified by 1 kb 
and 10 kb libraries in the three genomes. 
Venn diagrams showing the respective numbers of SVs in each library type and the overlap of SVs. 








        The comparison of the ability to identify SVs by the 10 kb and 20 kb libraries of K562 
showed a slightly higher detection rate of inversions and unpaired inversions for the 20 kb 
library and a higher detection rate of deletions for the 10 kb library (Table 2. 4). The span of the 
majority of the events from these two libraries was comparable, between 5 kb to 500 kb 
(Figure.2.7). One hundred and ninety-four deletions were identified by the 10 kb but not the 20 
kb library. The vast majority (188) were short deletions (< 20 kb). Sixteen deletions were 
specific to the 20 kb library and half of them had either both or one anchor region located in a 
repetitive region which could not be spanned by the 10 kb library (Figure 2.8). Similarly, tandem 
duplications which were exclusively identified by the 10 kb library were small in size (<20 kb). 
The 20 kb library-specific unpaired inversions or inversions which were missed by the 10 kb 
library showed a low cluster count or had one/both anchors located in repetitive regions.  
        After the comparison of the SVs from different insert size libraries, we combined the 
common SVs from different insert size libraries and obtained the genome-specific structural 
variations (Table 2.6, Appendix Table 1-3). In these three genomes, deletion and tandem 
duplication were the most abundant SVs whereas the number of inversion and insertion was less 
than other type of SVs.  HCT116 showed the lower number of complex SVs, suggesting a lower 




Figure 2.7. Comparison of number and span distribution of specific SVs identified by 10 kb 
and 20 kb libraries in K562. 
Venn diagrams showing the respective numbers of SVs in each library type and the overlap of SVs. 
















Figure 2.8. Example of a 20 kb library specific deletion in K562. 
(A) The drop of expected coverage (red track) in 10 kb and 20 kb library indicates the presence of a 
deletion. (B) The deletion only could be detected by a 20 kb library dPET cluster (cluster size 31) and the 
5’ and 3’ anchor span were 16,584 bp and 9,921bp. The red and pink arrows represented the 5’ and 3’ 
anchor regions of the dPET cluster. (C) The expected anchor span of 20 kb library is 20 kb and the 
segmental duplications (orange blocks) located at this deletion created the shorter anchor span in 20 kb 
library. The PETs of 10 kb library could not cross the segment duplications resulting in the failure to 
detect this deletion by the 10 kb library.  
 
Table 2.6. SVs identified in each genome 
  Isolated   Complex 
















MCF7 845 153 23 4 2 50 49 144 172 
HCT116 569 71 27 4 4 35 16 28 50 
K562 1393 145 52 16 9 83 38 247 260 
 
         
1)
      tandem duplication 
              2)
      unpaired inversion 
         




Validation of predicted SVs and Resolution of 1kb and 10kb libraries 
Genomic PCR and consequent Sanger sequencing were used to confirm the breakpoints of 161 
randomly selected SVs of the three genomes and a total of 129 SVs (80%) were confirmed 
(Table 2.7). Twenty of the 32 SVs which could not be validated had a cluster count <10 
indicating low cluster count represented a lower confidence of SV predication. Eight of the non-
validated SVs (cluster size 11 to 50) had shorter anchor spans which suggested that repetitive 
sequences around the breakpoints inhibited the PCR amplification or mapping error. The 
remaining two unpaired inversions (cluster counts 156 and 122) and two isolated translocations 
(cluster counts 113 and 245) were within complex regions with high supercluster count. The 
intersection of different breakpoints most likely inhibited the PCR amplification. 
      Table 2.7. Genomic PCR and Sanger sequencing validation statistics 
SVs Investigated Validated1) Non-validated2) Success% 
Deletion 62 51 11 82 
Tandem duplication 28 21 7 75 
Inversion 14 13 1 93 
Insertion 7 6 1 86 
Unpaired inversion 16 10 6 63 
Isolated translocation 34 28 6 82 
Total 161 129 32 80 
1)
 PCR products with single band at expected size range 
2)
 No  PCR products or PCR products with multiple bans 
   
We calculated the breakpoint resolution of 1 kb and 10 kb libraries and defined the resolution as 
the genomic distance in bp between the dPET clusters predicted breakpoint coordinate and the 
breakpoint coordinate determined by genomic PCR and Sanger sequencing. Inversions were 
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excluded from the resolution calculation as they tend to be located in repetitive regions which do 
not allow the unambiguous positioning of the breakpoints. In total, 244 breakpoints were used to 
calculate the resolutions (242 in 10 kb libraries and 140 in 1 kb libraries) (Table 2.8). For both 10 
kb and 1 kb library, the highest resolution was 0 bp and the lowest resolution for the 10 kb 
libraries was 10,799 bp and 1,205 bp for the 1 kb libraries. Importantly, the median resolution 
was 377 bp for 10 kb libraries and 115 bp for 1 kb libraries. This indicated that the higher 
coverage of the large insert libraries provides a resolution for the majority of breakpoints which 
is comparable to small insert libraries.  
        A large distance between the predicted breakpoints by dPET clusters and the true 
breakpoint locations is indicative of repetitive sequences which prevent a unique mapping. Of 
the 244 confirmed breakpoints, 104 were identified only by a 10 kb library, 138 were identified 
by 1 kb and 10 kb libraries, and 2 were identified only by a 1 kb library. Of all the 10 kb library 
specific breakpoints, 38/104 (36.5%) had a breakpoint resolution larger than 1.5 kb, whereas 
only 12/138 (8.7%) of 1 kb and 10 kb library common breakpoints had a resolution larger than 
1.5 kb (Figure 2.9. A; P < 10-9 [Fisher Exact Test]). Manual investigation of 10 kb specific 
breakpoints with resolutions larger than 1.5 kb showed that 33 of the 38 breakpoints (87%) had 
repetitive sequences covering the distances between predicted and true breakpoints, especially in 
the 1.5 kb regions next to the confirmed breakpoints (Figure 2.9. B). Only 4 of the 12 (33%) 1 kb 
and 10 kb common breakpoints were covered by repetitive sequences. The repetitive sequences 
were discontinuous and tags of the 1 kb dPET mapped to the gaps between the repetitive 
sequences allowing for the identification of the respective SVs (Figure 2.9. C). This strongly 
suggested that larger repetitive sequences around breakpoints prevent mapping of tags of 1 kb 
libraries and hence the identification of the respective SVs.  
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Table 2.8. Breakpoint resolution of 1 kb and 10 kb libraries 
 







  1kb 10kb 1kb 10kb 1kb 10kb 1kb 10kb 1kb 10kb 1kb 10kb 
Breakpoints 140 242 54 100 28 42 12 20 36 56 10 24 
Highest (bp) 1) 0 0 4 0 5 2 28 15 0 3 51 93 
Lowest (bp) 2) 1,205 10,799 1,067 5,788 878 6,930 613 1,407 1,123 10,799 1,205 9,668 




 Highest: The smallest difference between the genomic PCR and Sanger sequence confirmed breakpoints and DNA-PET predicted breakpoints 
 
2)
 Lowest: The largest difference between the genomic PCR and Sanger sequence confirmed breakpoints and DNA-PET predicted breakpoints 
 3)






Figure 2.9. Breakpoint resolution and repetitive sequences of 1 kb and 10 kb   
                    libraries specific and common SVs 
 
(A) Breakpoints confirmed by PCR and Sanger sequencing and their resolution (defined as 
the distance in bp between the predicted and actual breakpoints. (B) A 10 kb library specific 
deletion in MCF-7. The genomic PCR and Sanger sequencing confirmed left and right 
breakpoints are chr9:22,486,527 and chr9:22,494,345, respectively. The resolution of the left 
and right sides of the deletion are 906 bp and 4,683 bp, respectively. Repetitive sequence 
which does not allow unambiguous mapping covers the entire 4,683 bp region. The repetitive 
sequence could not be spanned by the 1 kb library preventing the identification of this 
deletion. (C) A deletion in MCF-7 identified by both 10 kb and 1 kb libraries. The left and 
right breakpoints confirmed by genomic PCR and Sanger sequencing are at chr3:6,625,155 
and chr3:6,629,779, respectively. Based on the 10 kb library predicted breakpoints, the 
resolution on the left and right sides of the deletion are 973 bp and 2,216 bp, respectively.  
The tags of the 1 kb library mapped to the gap (in orange) between the repetitive sequences 







Copy number analysis by PET 
Genomic rearrangements, such as deletion, tandem duplication, insertion and isolated 
translocation, give rise to copy number variations (CNVs) in the cancer genome 
(Shaikh et al. 2009). CNV is one of the key genetic drivers of diseases such as cancer 
(Beroukhim et al. 2010). Karyotyping, FISH and aCGH have been extensively used in 
genome-wide CNV prediction. More recently, the high-throughput sequencing for 
whole genome at high coverage has motivated the mapping of genome-wide CNVs 
using sequenced reads mapped onto the reference genome, based on the fact that the 
number of reads mapped to a genomic region is expected to be proportional to its 
copy number (Campbell et al. 2008; Xie et al. 2009). The copy number estimates and 
genomic rearrangements acquired from paired-end sequencing data have revealed the 
relationship between genomic breakpoints and amplicons or deletions (Pleasance et al. 
2010a; Pleasance et al. 2010b; Stephens et al. 2009). 
        We analyzed the copy number changes across the genome of MCF-7, HCT116 
and K562 by computing the density of all cPETs from 10 kb libraries. By comparison 
of the GC content from different size libraries, we confirmed that the GC bias in each 
library was due to the sample preparation step, but not from sequencing platform. 
Then the GC bias was corrected by calculating the GC content of the corresponding 
sliding windows along the genome. Another advantage of using cPET tags was to 
reduce the PCR amplification error by keeping one of the PETs which were mapped 
to the exact locations. The result showed that four significant amplified regions of 
MCF-7 are located on chromosome 1, 3, 17 and 20 (Figure 2.10); three amplified 
regions in K563 genome are located on chromosome 9, 13 and 22 whereas there is no 
significant amplified region could be found in HCT116 genome.  The copy number 
prediction of MCF-7 was compared with the copy number estimation for MCF-7 by a 
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244K array comparative genomic hybridization (aCGH) as a validation and the result 
showed a correlation of r2=0.776 (Figure. 2.11). In addition, copy number estimation 
using sequencing data produced more and smaller copy number segments, 257 by 
aCGH and 714 based on cPET tags.   
MCF-7 10 kb PET
HCT116 10 kb 
K562 10 kb PET
 
Figure 2.10. Whole genome copy number of the three genomes estimated by 
cPET tags of 10 kb libraries. 
The green and black dots represent copy number of the probes or windows of each 




Figure 2.11. Correlation of copy number estimation for MCF-7 by aCGH and 
high throughput PET sequencing. 
The estimated copy number of genomic segments of at least two adjacent windows with the 
same copy number estimate (y-axis) were correlated with copy number estimates by aCGH 
(x-axis): r2=0.7763. 
 
A large homozygous deletion identified in K562 by CNVs analysis 
Large homozygous deletions (HDs) of recessive cancer genes result in their 
inactivation and are driver mutations. Several HDs related recessive cancer genes had 
been found in cancer genomes, including CDKN2A, RB1, SMAD4, SMARCB1, 
MAP2K4 and PTEN (Bignell et al. 2010). An around 6 Mb HD from a gene-rich 
region on chromosome 9 of K562 was uncovered by CNVs analysis. MCF-7 and 
HCT116 had normal copy number in the same region indicated that this deletion was 
not wrongly picked up by mapping error. However, this deletion had no dPET cluster 
supporting. After close investigation of the boundary of the deletion, we found the 
repetitive sequence located at the 5’ boundary of the deletion, which made it hard for 
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the dPETs to map. Because of the repetitive sequence, we also could not validate this 
large deletion by genomic PCR and Sanger sequencing. However, this deletion could 
be validated by FISH. We used 4 probes, two of them located at the boundary of the 
deletion (22m4 and 42d9) and the other two  located inside the deletion (66p3 and 
781g24), and we also used rp11-10619 of chromosome 9 as a positive control. The 
FISH result clearly showed that the positive control and the two probes located at the 
boundary of the deletion had signals and the two probes located inside the deletion 
had no signal (Figure 2.12).  There are 37 genes in this 6 Mb HD region, including 
important tumor suppressor gene CDKN2A (Table 2.9). The function of this large HD 









Figure 2.12. A 6 Mb homozygous deletion identified by copy number analysis in 
K562. 
 (A) The copy number from 19 Mb to 28 Mb on chromosome 9 in K562, MCF-7 and HCT116. 
The red track represents the coverage of the cPETs. (B) The FISH validation result of the 
deletion. Green color was the positive control probe (rp11-106l9: 133087269-133237519, 
9q34). Red color was the two probes located outside of the deletion (rp11-42d9: 20560274-
20736915, 9p21, rp11-22m4: 26686497-26890847, 9p21). The two probes located inside of 
the deletion (rp11-66p3: 20784480-20945583 9p21, rp11-781g24: 26409244-26590208 9p21) 




Table 2.9. Genes located in the HD of chromosome 9 in K562 









9 23490689 23662385 171696 CR627240 1.5477283 1.814947185 0.144898 
9 20993624 21021635 28011 PTPLAD2 1.6929134 2.469914531 0.178242 
9 22103664 22111093 7429 BC038540 1.4119948 1.743757167 0.120022 
9 21792634 21855969 63335 
OK/SW-
cl.18 1.0454269 2.096723198 0.174368 
9 25666386 25668856 2470 TUSC1 2.0256638 2.41054782 0.240052 
9 22436839 22442472 5633 DMRTA1 2.1784669 1.847565768 0.184567 
9 21984789 22111093 126304 NR_003529 1.1096129 2.114499375 0.180428 
9 21374253 21375396 1143 IFNA2 1.7698008 2.39955456 0.196489 
9 21984789 22067889 83100 DQ485454 0.8251085 2.051911687 0.172847 
9 21984789 22067889 83100 EU741058 0.8251085 2.051911687 0.172847 
9 21314053 21325388 11335 KLHL9 1.5641342 1.7341566 0.159599 
9 21314053 21325352 11299 KIAA1354 1.5640891 1.73353197 0.159572 
9 21357422 21358075 653 IFNA13 2.7636389 3.505685627 0.3296 
9 21470838 21472312 1474 IFNE1 2.0017366 2.324474181 0.225805 
9 21130630 21132144 1514 IFNW1 1.3476992 1.739301789 0.160341 
9 21444269 21549832 105563 LOC554202 1.7690235 2.399963616 0.217364 
9 21294685 21295255 570 IFNA5 1.870899 2.399261484 0.224914 
9 25770053 25802963 32910 BC043546 1.6693268 1.914709123 0.194982 
9 21992901 21999312 6411 CDKN2B 0.8952875 2.09989774 0.198389 
9 21067103 21067943 840 IFNB1 1.6575034 2.177937864 0.18738 
9 21196179 21197142 963 IFNA10 4.9191668 6.486508203 0.605519 
9 21191233 21229990 38757 IFNA14 4.9191668 6.486508203 0.605519 
9 21229200 21229978 778 IFNA14 4.9191668 6.486508203 0.605519 
9 21206371 21207310 939 IFNA16 4.9191668 6.486508203 0.605519 
9 21217241 21218221 980 IFNA17 4.9191668 6.486508203 0.605519 
9 21191467 21192204 737 IFNA7 4.9191668 6.486508203 0.605519 
9 21792634 22019593 226959 MTAP 0.6286156 2.173512882 0.217575 
9 21430439 21431315 876 IFNA1 1.9597469 2.204164272 0.267893 
9 21957750 21984490 26740 CDKN2A 0.3523075 1.537529827 0.147506 
9 23680102 23816063 135961 ELAVL2 1.4054098 1.829944442 0.205783 
9 21399145 21400184 1039 IFNA8 1.3447016 1.65955186 0.224819 
9 22636198 22814212 178014 AX747623 1.6427039 2.334283188 0.277427 
9 21267686 21268562 876 V00539 2.1598289 2.779296382 0.338708 
9 21155635 21156659 1024 IFNA21 3.5544332 4.186883793 0.502616 
9 21176692 21177670 978 IFNA4 3.5544332 4.186883793 0.502616 
9 21340316 21340886 570 IFNA6 1.5108888 2.220981059 0.359903 
9 20648308 20985954 337646 KIAA1797 1.9466031 2.515487544 0.606575 
(1)
 gene span: gene end minus gene start 
(2)




Reconstruction of the BCR-ABL1 amplicon of K562 by fusion point guided 
concatenation 
The identification of SVs by paired-end sequencing provides a detailed understanding 
of local genomic structures. However, cancer genomes frequently show complex 
rearranged amplifications. To reconstruct these complex rearrangements, a collective 
analysis of the rearrangement points is required. We therefore employed a fusion-
point-guided-concatenation algorithm (see Materials and Method) to jointly visualize 
genomic segments surrounding the translocation (chr9/chr22) which creates the CML 
causing fusion gene BCR-ABL1 (Groffen et al. 1984) in K562 (Figure 2.14. D). The 
analysis showed that i) the disease causing rearrangement point had the highest dPET 
cluster size (692) supporting the concept of amplified rearrangement points as 
indicators of driver events (Hillmer et al. 2011); ii) five different chromosomes (1, 3, 
9, 13, and 22) were involved in this amplification, and iii) the core region was located 
in different genomic contexts indicated by alternative paths at the edges of the 
amplicon (Figure 2.14. A). To place the amplicon picture in a cytogenetic context, we 
analyzed the three most amplified rearrangement points (largest dPET clusters) by 
FISH (Figure 2.14. B-C). The FISH analysis confirmed the amplification of the fusion 
points and showed that the amplicon was distributed over two marker chromosomes. 
Further, a subpopulation of the BCR-ABL1 amplicon path connecting chromosome 9 
at 133.1 Mb with chromosome 22 at 15.7 Mb (dPET cluster count 218) but not the 
path connecting chromosome 9 at 133.2 Mb with chromosome 13 at 107.5 Mb was 
located on chromosome 2q.  
      We also reconstructed the whole genome rearrangement of MCF-7, HCT116 and 
K562 by this fusion-point-guided-concatenation algorithm using all the dPET clusters 
with count ≥ 3 and the detail can be found in the appendix data. 
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Figure 2.13. Reconstruction of the BCR-ABL1 amplicon of K562. 
 (A) Concordant tag distributions representing copy number are shown for amplified genomic 
regions (top, green track). Genomic segments between predicted breakpoints are indicated by 
colored arrows and dPET clusters with cluster sizes greater than 35 of predicted somatic 
rearrangements are represented by horizontal lines flanked by dark red and pink arrows 
indicating 5’ and 3’ anchor regions (middle). Small to large dPET clusters are arranged from 
top to bottom. Cluster sizes are indicated. High dPET cluster size of the CML causing BCR-
ABL1 translocation suggests that the rearrangement occurred early and that it has 
subsequently been amplified. Fusion points I-III correspond to panel c-d. (B) Fluorescence in 
situ hybridization (FISH) of BCR-ABL1 rearrangement (fusion point I with cluster size 692). 
Red RP11-83J21 probe (chr9:132,641,829-132,818,294) and green RP11-61N10 probe 
(chr22:21,728,292-21,917,898) spanning the fusion point are hybridized on K562 cell line. 
Yellow spots represent fusion signals and illustrate the amplification of BCR-ABL1. (C) FISH 
analysis of metaphase chromosomes of three high copy fusion points: I) probes as described 
in b show fusion signals on two marker chromosomes and on chromosome 2q and normal 
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localization on both rearranged chromosomes 9 and normal chromosome 22; the fusion on 
chromosome 2 has not been identified by DNA-PET most likely due to low sequence 
complexity at the break point or complex rearrangements, II) green RP11-106I9 probe 
(chr9:133,087,269-133,237,519) and red RP11-83J21 probe (chr13:107,393,170-107,577,262) 
spanning the fusion point II (cluster size 259) show fusion signals on the same marker 
chromosomes and normal localization on both normal and rearranged chromosomes 9 and 13, 
III) red RP11-544A12 probe (chr9:132,955,072-133,152,093) and green RP11-104F9 probe 
(chr22:15,547,686-15,730,740) spanning fusion point III (cluster size 218) show fusion 
signals on the same marker chromosomes and normal localization on both normal 
chromosome 22 and rearranged chromosomes 9. (D) Contigs (indicated by boxes) which were 
covered by PET mapping were concatenated by fusion-point-guided-concatenation method. 
The length of a contig is represented by the length of the box. Because of the size difference 
between chromosomes 1, 3, 9, 13, and 22, the length of chromosome 22 is represented by the 
length of contig/10,000 while the lengths of chromosomes 1, 3, 9, and 13 are represented by 
the length of contig/100,000. Any value less than 0.1 is rounded to 0.1; any value larger than 
6 is rounded to 6. The thickness of borders of each contig represents the coverage (copy 
number). Red dashed edges represent dPET edges, while black bold edges represent cPET 
edges. The thickness of dPET edges represents the size of the corresponding dPET cluster. 
cPET edges have uniform thickness. Arrow heads pointing towards a contig indicate 
connections with the lower coordinates, arrow heads pointing away from a contig indicate 
connections with the higher coordinates.  
 
DISCUSSION 
The PET sequencing has become a key technique to assess genome rearrangements 
and SVs in normal and cancer genomes (Clark et al. 2010; Fujimoto et al. 2010; 
Hillmer et al. 2011; Lee et al. 2010; McKernan et al. 2009; Pleasance et al. 2010b; 
Stephens et al. 2009). However, some characteristics are still not well understood 
regarding study design and the balance of cost versus benefit of different sequencing 
strategies. One such factor is the choice of the most suitable sequencing library insert 
size. Using a quantitative study, Bashir et al. concluded that larger clones could 
maximize the clonal coverage and detect as many rearrangement breakpoints as 
possible while reducing the sequence effort, whereas smaller clones could provide 
better localization (Bashir et al. 2008). This conclusion was confirmed by Bentley and 
McKernan, who observed that when using different insert sizes, most of their 
predictions were unique to one data set, and the probability of detecting a breakpoint 
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with a combined library was higher than using only one type of library (Bentley et al. 
2008; McKernan et al. 2009). However, 200 bp to 3 kb insert sizes are not large 
enough since only lengths of  > 7 kb are expected to span common transposon 
insertions such as L1s (the canonical L1 element is 6 kb long) (Cordaux et al. 2009)  
and thereby can identify insertion events in a single read. Using three cancer cell lines, 
MCF-7, HCT116, and K562 as test genomes, we sequenced different insert size 
libraries (1 kb, 10 kb, and 20 kb) to identify SVs. The comparison of different insert 
size libraries demonstrated that the PET sequencing strategy with large insert sizes 
(10 kb) is an attractive whole-genome sequencing approach to identify SVs in human 
genomes. With the same sequencing effort, the 10 kb libraries could identify more 
and larger SVs, whereas the 1 kb libraries were advantageous in identifying deletions 
with span < 5 kb. In addition, 10 kb libraries had a comparable resolution in 
predicting breakpoint locations to a distance that can be amplified by PCR. The 20 kb 
insert size library had a slight advantage in discovering inversions and unpaired 
inversions but displayed a lower sensitivity in identifying small SVs of various 
categories compared to 10 kb insert size library. The construction of libraries with 20 
kb inserts requires more genomic DNA starting material compared to 10 kb insert 
libraries. The detailed characterizations of SVs by large insert size libraries showed 
many new sub-types of insertions, which could help in understanding the genesis and 
effect of insertions in human normal and cancer genomes.  
        This study is complementary to those that have investigated the effect of read-
lengths and library-size on the ability to do de novo assembly of the data (Chaisson et 
al. 2009; Nagarajan et al. 2009; Wetzel et al. 2011). In a recent work (Wetzel et al. 
2011) the authors suggest that multiple library sizes are needed to optimally resolve 
various classes of repeats. While larger library sizes allow the spanning of more 
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repeat classes the associated complexity of assembly analysis also increases. These 
considerations make the choice of library-size for de novo assembly less clear-cut 
when compared to reference-guided SV analysis. 
      With the rapid development of next generation sequencing technologies, whole 
genome sequencing has become an invaluable tool for obtaining a complete 
understanding of human genomic variation. In the future, personal genomic 
information will gain importance to tailor an individual’s medical care. Our study 
provides valuable information on the characteristics of PET sequencing libraries and 
such information will help to select appropriate and most effective insert sizes for 
various kinds of sequencing projects. 
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Chapter Three: Long Span PET Mapping Reveals Characteristic Patterns of Structural 
Variations in Epithelial Cancer Genomes 
Introduction 
Many important cancer genes have been identified at translocation breaks in leukemias, 
lymphomas and sarcomas, by contrast, the possibility that fusion genes might be present in the 
common human epithelial cancers, such as colorectal and breast carcinoma, was largely ignored 
(Edwards. 2010). We have a relatively good understanding of the genes which can be point-
mutated, amplified or deleted in these cancers, however, the large number and the complexity of 
genome rearrangements has made it difficult to identify all genes at chromosome breakpoints. It 
has been widely assumed that gene fusions do not contribute significantly to carcinomas, 
however, the identification of TMPRSS2-ERG in prostate cancer (Tomlins et al. 2005) and 
EML4-ALK in lung cancer (Soda et al. 2007) confirmed that fusion genes are also present in 
solid tumors, but that their detection has been hampered for technical reasons.  
        The limited knowledge of chromosome rearrangement in the common cancer is due to the 
lack technologies which allow a comprehensive analysis. Traditional cytogenetic approaches 
require metaphase chromosome preparations and therefore cell lines which are not easy to 
establish from a large number of primary tumors. In addition, the complexity of carcinoma 
karyotypes renders the identification of rearrangements by cytogenetic banding challenging and 
prone to errors (Adeyinka et al. 2000). Until the last year or two, it has not been technically 
feasible to systematically find genomic rearrangements. The genomic rearrangements identified 
in carcinomas were found by indirect methods that can be applied only for particular fusions. 
However, two complementary approaches led us to a new era. One approach derived from 
molecular cytogenetics, i.e. FISH and CGH; while the other uses new sequencing technologies.  
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        The introduction of a new generation of DNA sequencers has provided a different way to 
systematically discover genome rearrangements. There are two approaches to discover genome 
rearrangements by DNA sequencing. In the first approach, fragmented genomic DNA or cDNA 
can simply be sequenced at random and can be compared to the reference genome and 
transcriptome. This has worked very well when applied to cDNA (Guffanti et al. 2009) but it is 
too expensive when applied to the whole human genome. The second approach is “paired end 
read”, where only the two ends of long genomic DNA fragments are sequenced. The paired end 
sequencing approach is very well suited for the discovery of genomic rearrangements. A 
particular strength is that it can be applied to DNA of both, tumor and cell lines. Recently 15 
breast primary tumor and 9 immortal breast cancer cell lines had been sequenced by paired-end 
sequencing in order to understand the patterns of somatic rearrangement in breast cancer 
genomes (Stephens et al. 2009). A total of 2,166 confirmed somatic rearrangements were 
identified among the 24 cancers. However, there is substantial variation the frequency of somatic 
rearrangements across cancer samples. Overall, breast cancer cell lines showed more 
rearrangements (median 101, range 58-254) than primary tumors (median 38, range 1-231). This 
difference may be due to the acquisition of additional rearrangements during in vitro cultures or 
the contamination of normal tissue which renders the detection of somatic events more difficult 
or the relative propensity of some subclasses of breast cancer to become established in culture.  
        Many novel in-frame fusion genes or internally rearranged genes were identified and most 
of them were expressed. However, none of them was recurrent. It is more likely that most are 
passenger events and much larger series will be required to investigate comprehensively the 
possibility of recurrent cancer-causing rearrangements in breast cancer. This study gives insight 
into the complexity of rearrangement patterns in solid tumor genomes and shows that most 
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rearrangements in breast cancer are intrachromosomal. Breast cancers are highly heterogeneous 
and the prevalence of tandem duplications can be used to subclassify breast cancer. Breast 
cancers with many tandem duplications are usually oestrogen- and progesterone-receptor 
negative and classified by expression profile as basal-like. In contrast, cancers with few 
rearrangements or with rearrangements in amplicons are usually oestrogen-receptor positive and 
are classified as luminal A and luminal B types, respectively (Stephens et al. 2009). Although 
this study was restricted to breast cancer, many of the findings will also be relevant for other 
common cancers, and they are consistent with a preceding pilot study of two lung cancer cell 
lines (Campbell et al. 2008).  
        Recently, five studies described the application of genome analysis techniques to a range of 
breast cancer. Curtis and colleagues analyzed copy number, sequence changes known as single 
nucleotide polymorphisms, and gene-transcription rates in approximately 2,000 breast cancers 
which included all known breast cancer types (Curtis et al. 2012). Around 40% of genes’ 
expression were associated with inherited variants (copy number variants and single nucleotide 
polymorphisms) and acquired somatic copy number aberrations (CNAs). Three putative cancer 
genes were identified, including deletions in PPP2R2A, MTAP and MAP2K4.  
         In order to comprehensively understand the driver mutations and mutational processes 
operative in breast cancer, the genomes of 100 tumors for somatic copy number changes and 
mutations in the coding exons of protein-coding genes had been sequenced (Stephens et al. 2012). 
The results showed that at least 40 cancer genes were implicated in the development of the 100 
breast cancers, including point mutations and/or copy number changes. The maximum number of 
mutated cancer genes in an individual cancer was 6, but 28 tumors only showed a single driver. 
In some cases, the presence of multiple drivers was associated with subclonal evolution of the 
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cancer. Several new cancer genes were identified, including AKT2, ARID1B, CASP8, CDKN1B, 
MAP3K1, MAP3K13, NCOR1, SMARCD1 and TBX3. Among the 100 tumors, 73 different 
combinations of mutated cancer genes had been found and this strongly highlighted the 
substantial genetic diversity underlying this common disease.  
         Primary triple-negative breast cancer (TNBC) is a tumor type defined by lack of oestrogen 
receptor, progesterone receptor and ERBB2 gene amplification, which represent approximately 
16% of all breast cancers. Shah et al. assessed mutations, cop number and gene expression in 
104 TNBC cases and found that the frequencies of copy number abnormalities and mutations 
vary markedly between and within the tumors, which indicates that mutations can arise at 
multiple stages of tumor progression (Shah et al. 2012). Three genes including TP53,   PIK3CA 
and PTEN, are involved in the early stages of breast-cancer development. Interestingly, only 
one-third of the low-prevalence mutated genes identified by this study were transcribed into 
RNA, which suggests that they may be chance mutations unrelated to the cancer and/or the 
mutations involved genes with tumor-suppressive activity.  
         Ellis and colleagues studied pretreatment tumor biopsies accrued from patients in two 
studies of neoadjuvant aromatase inhibitor therapy to correlate the variable clinical features of 
oestrogen-receptor-positive breast cancers with somatic alterations (Ellis et al. 2012).Eighteen 
significantly mutated genes were identified, among of them, five genes (RUNX1, CBFB, MYH9, 
MLL3 and SF3B1) were reported to be related with haematopoietic disorders. The researchers 
also showed that compared to the tumor cells with lower Ki67 protein expression, the tumor cells 
with a higher expression level were associated with resistance to aromatase inhibitors and 
contained more somatic mutations and genome structural changes. This finding implicated 
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genetic changes which lead to deregulation of DNA replication and repair processes in this drug 
resistance.  
         In the last study, Banerji and colleagues examined whole-exome sequences of DNA from 
103 human breast cancers of diverse subtypes and whole-genome sequences of 22 breast 
cancer/normal pairs (Banerji et al. 2012). Besides confirming recurrent somatic mutations in 
PIK3CA, TP53, AKT1, GATA3 and MAP3K1, recurrent mutations in the CBFB transcription 
factor gene and deletions of its partner RUNX1 were also discovered. Moreover, a recurrent 
MAGI3-AKT3 fusion was identified to be enriched in TNBC. The MAGI3-AKT3 fusion led to 
constitutive activation of AKT kinase, which is abolished by treatment with an ATP competitive 
AKT small-molecule inhibitor.  
        Gastric cancer is also a heterogeneous disease with multiple environmental etiologies and 
alternative pathways of carcinogenesis. Besides mutations in TP53, changes in other genes or 
pathways only account for small subsets of the disease. In order to identify previously unreported 
mutated genes and pathway alterations, 22 gastric cancer samples had been studied by exome 
sequencing (Wang et al. 2011) and the result showed that genes involved in chromatin 
modification to be commonly mutated. Furthermore, the mutation spectrum for ARID1A, which 
encodes a member of the SWI-SNF chromatin remodeling family, differed between molecular 
subtypes of gastric cancer and mutation prevalence was negatively associated with mutations in 
TP53.  
         To explore the spectrum of somatic mutations in gastric cancer, the exomes of 15 gastric 
adenocarcinomas and their matched normal DNAs were sequenced (Zang et al. 2012). The 
frequently mutated genes included TP53, PIK3CA and ARID1A. Cell adhesion was the most 
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enriched biological pathway among the frequently mutated genes. Around half of the gastric 
cancers had mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) and 8% of 
primary tumors had ARID1A mutations. A cadherin family gene, FAT4, was confirmed to be 
mutated in 4% of gastric tumors. The functional assays showed that both FAT4 and ARID1A to 
exert tumor-suppressor activity. Somatic inactivation of FAT4 and ARID1A may be the key 
tumorigenic events in a subset of gastric cancers. 
        All these studies are remarkable testament to the power of genomic technologies to define 
the landscape of a complex disease state, and give us the most thorough view yet of the 
molecular underpinnings of breast and gastric cancers. In this chapter, we applied the 10 kb long 
span paired-end-tag sequencing and mapping strategy to two epithelia cancers, i.e. breast and 
gastric cancer. We comprehensively mapped genome SVs of eight breast cancer samples 
including five primary breast cancer tumors and three well established cell lines (MCF-7, T47D, 
and SKBR3), five gastric cancer samples including four primary gastric cancer tumors and one 
cell line (TMK1). These are contrasted to genomes of a colon cancer cell line (HCT116), a 
chronic myelogenous leukemia (CML) cell line (K562), and 2 normal individuals (an African 
and a European). Cross comparison of the cancer and normal genomic maps enabled us to 
distinguish possible somatic rearrangements from germ line events, and revealed characteristic 
patterns of SVs that are prominent in breast and gastric cancer genomes. Using the connectivity 
and quantitative nature of the DNA-PET data, we delineated the genealogy of rearrangement 
events involved in amplified regions in individual cancer genomes, and elucidated potential 




Genomic DNA-PET sequencing and mapping 
The genomic DNAs of 17 human genomes were sheared randomly and gel purified in 10 kb size 
range (Figure 3.1, breast tumor 13 DNA was purified in 5 kb range due to limited DNA quality). 
The DNA fragments of each genome were processed for PET construction and paired-end 
sequencing analysis. In total we generated >25.9 Giga bases of DNA sequence derived 
from >476 million non-redundant PET sequences from these 17 genomes and achieved, on 
average, 81-fold physical (fragment) coverage of each genome (Table 3.1). Five libraries, 
including the European normal genome, MCF-7, two gastric tumors and TMK1, have achieved 
more than 100-fold physical coverage due to either larger fragment size or more sequence reads.  
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Figure 3.1. DNA-PET libraries insertion size distribution. 
DNA insertion size peaks range from 5 kb (breast tumor 13) to 11.5 kb (MCF-7). The majority of 
libraries show inserts with a size of 10 kb. Breast tumor 14 showed PCR caused spikes which have been 
excluded for this presentation. 
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Classifying cPET and dPET 
With the continuous optimization of library construction protocol, the libraries constructed at the 
late stage of this project had much sharper library span compared to the libraries constructed at 
the early stage (Figure 3.1). Therefore, in some cases the gradient used to determine the 
minimum span point of particular library (see Materials and Methods for Chapter 2) did not 
reach 0 or reached 0 much further from the expected point. Therefore we have defined the cutoff 
gradient as 0.01 x Maximum gradient. The first point at which this gradient occurred was 
considered as the minimum span of the libraries. Similarly the maximum span was determined as 
the first point to the right of the minimum gradient point where the gradient reached 0.01 x 
Minimum gradient (Figure 3.2). This definition gave very similar cutoffs compared to the 
SOLiD pipeline Corona Lite version 4.0.2 cutoff for the rescue window which was introduced at 
the later stage of the project. The Corona Lite version 4.0.2 cutoff definition was used for 
libraries IHT009 and DHG003. The vast majority of PET sequences (89%) were cPETs and the 














                   
Figure 3.2 Gradient based span cutoff compared to standard deviation based cutoff. 
Frequencies of library insert sizes for two DNA-PET libraries are shown in black (IHH027, European; 
IHB002, Breast tumor 2). Below and above median standard deviations (BMSD and AMSD, respectively) 
are shown in blue, brown, and green for 1, 2, and 3 standard deviations, respectively. Gradient based 
definition of minimum and maximum cPET are shown in red. Note that for IHB002, 2 AMSD (12,112) 
and the maximum cPET cutoff (12,163) are superimposed. 
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Table 3.1 Statistics of massively parallel PET sequencing of each genome. 
Sample Tags Mappable Tags PET PET (NR)1 cPET2 span cPET (NR)1 Coverage3 dPET4 (NR)1 dPET4 cluster5 
      range [bp]     
European 366,708,248 200,414,308 64,350,297 43,646,070 7,400-10,977 40,682,877 130.1 2,963,193 666 
African 251,094,242 122,504,474 34,441,940 27,013,890 7,132-9,854 24,075,215 71.5 2,938,675 356 
Breast tumor 1 353,330,838 217,285,714 86,355,790 5,454,539 8,323-12,436 4,705,578 16.8 748,961 313 
Breast tumor 2 217,007,124 134,511,878 50,962,000 10,951,889 7,742-12,163 10,214,722 34.9 737,167 426 
Breast tumor 5 496,450,386 280,659,839 78,184,988 10,276,850 8,109-12,120 6,710,288 23.8 3,566,562 242 
Breast tumor 13 580,449,070 335,245,735 108,789,285 38,594,882 4,012-6,325 34,746,195 61.4 3,848,687 957 
Breast tumor 14 727,464,383 355,410,533 95,183,702 22,615,058 7,592-12,520 16,603,012 57.2 6,012,046 434 
MCF-7 362,405,602 150,722,313 35,438,575 28,518,121 8,099-16,217 25,208,550 101.1 3,309,571 1,047 
SKBR3 357,021,381 228,828,267 83,688,064 25,624,846 7,229-9,639 23,253,608 68.4 2,371,238 1,145 
T47D 177,908,044 90,297,366 26,564,983 14,718,535 7,816-11,617 12,997,188 44.5 1,721,347 376 
Gastric tumor 17 622,317,436 234,345,611 53,012,028 42,039,629 8,630-11,310 40,195,339 140.5 1,844,290 1,126 
Gastric tumor 26 407,475,701 250,309,081 84,647,235 14,603,105 8,108-11,653 11,798,863 40.1 2,804,242 586 
Gastric tumor 28 270,976,929 157,958,274 51,743,377 32,832,641 8,152-11,786 30,557,538 106.3 2,275,103 1,238 
Gastric tumor 38 351,714,141 194,346,844 48,868,556 28,728,468 7,561-11,503 24,491,622 79.8 4,236,846 550 
TMK1  501,758,330 306,105,871 110,164,772 67,903,728 8,760-11,920 64,162,963 233.3 3,740,765 1,253 
HCT116 492,180,222 292,721,687 72,893,710 28,262,465 7,200-11,780 24,599,666 77.0 3,662,799 883 
K562 376,077,182 223,850,946 133,675,193 34,759,699 6,846-10,248 31,240,240 91.9 3,519,459 939 
 
1)
 non redundant  
2)
 concordant PET  
3)
 physical coverage  
4)
 discordant PET 
5)
 clusters of size ≥ 3  
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Purifying dPETs clusters 
Among the dPETs (11% of PET sequences), the most prominent dPET categories were small 
span PETs (median of 17 libraries = 4.07% of total PETs) and different chromosome PETs 
(median of 17 libraries = 4.53% of total PETs; Figure. 3.3). Some libraries (i. e. constructed at 
the beginning of this project with larger standard deviation had a large fraction of small span 
PETs (Table 3.2) with the extreme of 21.43% of all PETs having a small span for breast tumor 
14. All small span PETs were excluded from further SVs analysis since they interfered with the 

















































































Figure 3.3. Frequencies of non-cPET categories of 17 DNA-PET libraries. 
Non-cPETs of each library were categorized in the five shown categories as described in Materials and 
Methods of Chapter 2 ‘PET classification’. Fraction of PET counts of each category compared to total 
PET counts per sample is presented. Fractions of 17 libraries are summarized by box plots. Thick 
horizontal lines indicate medians, boxes represent values of libraries from the 25th to 75th percentile, 




Table 3.2:  Median and standard deviations of DNA-PET library inserts 
 






IHH027 European 9,103 636 577 
IHH022 African 8,294 2,697 1,281 
IHB001 Breast tumor 1 9,909 2,271 1,183 
IHB002 Breast tumor 2 9,449 2,403 1,332 
IHB005 Breast tumor 5 9,785 2,931 1,590 
IHB013 Breast tumor 13 4,954 974 548 
IHB014 Breast tumor 14 9,338 3,318 2,046 
IHM005 MCF7 10,198 2,515 1,314 
IHM006 MCF7 11,972 2,779 1,624 
IHS012 SKBR3 8,279 815 524 
IHT008 T47D 9,599 2,217 1,038 
DHG003 Gastric tumor 17 10,011 848 505 
IHG009 Gastric tumor 26 9,561 1,997 899 
IHG005 Gastric tumor 28 9,785 2,396 1,111 
IHG006 Gastric tumor 38 9,188 1,726 867 
IHT009 TMK1 10,347 653 562 
IHH003 HCT116 9,711 3,383 1,710 
IHH020 HCT116 9,282 1,140 685 
IHH026 HCT116 8,513 562 526 
IHK006 K562 8,305 643 594 
IHK007 K562 8,304 655 597 
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        During construction of a DNA-PET library, chimeric ligation products occur and it is more 
likely that two randomly ligated genomic DNA fragments are of different chromosomes than 
from the same chromosome. Similarly, dPETs creating mapping artifacts due to sequence 
similarity between two different genomic regions are more likely to occur inter-chromosomally. 
In the 17 DNA-PET libraries we observed >56 million different chromosome PETs (including 
redundant reads) representing >90% of all dPETs after excluding the short span category. Only 
23,900 different chromosome PETs formed 999 inter-chromosomal clusters, representing 8% of 
all dPET clusters. We also conducted a simulation study where we generated 100 random 
datasets of chimeric PETs (14.6 million of them = 11% of 133 million, the number of PETs in 
the largest library in this study [K562]) and clustered them. While on average, each dataset had 
nearly 130 size 2 clusters, only one of the datasets had a single, count 3 cluster, which strongly 
confirming that such artifacts are unlikely in our results when using cluster count 3 as cut off.  
              For libraries IHB002, IHB005, IHB014, IHH022, and IHT008, the span window for the 
rescue mapping procedure (detail see Material and Methods for Chapter 2) was larger than the 
window used to define the cPET cutoff. These rescued PETs caused large numbers of artifactual 
dPET clusters of the category: same chromosome, same strand, correct ordering and larger span 
distance. These artifacts were removed by excluding from further analysis all clusters of the 
category same chromosome, same strand, correct ordering with a distance smaller than the 
rescue window between the start of the 5’ anchor and the start of the 3’ anchor (corresponding to 
StartL and StartR in appendix data, Table 13) or the end of the 5’ anchor and the end of the 3’ 
anchor (corresponding to EndL and EndR in appendix data, Table 13). dPET clusters with 
anchor regions <1 kb for 10 kb libraries and <500 bp for the 5 kb library of breast tumor 13 and 
clusters within 1 Mb of centromeres were excluded from further analysis. 
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Detection of rearrangement points and structural variations (SVs) 
After dPETs clusters purification and using cluster count 3 as cut off (Figure 3.4), the numbers of 
rearrangement points (the junction of two genomic breakpoints) identified by dPET clusters in 
the 17 genomes ranged from 242 in breast tumor 5, to 1,255 in the gastric cancer cell line TMK1 
(Table 3.1). By plotting the increasing curve of dPET clusters against the sequencing depth (non-
redundant PETs), it is estimated that with 27 million or more non-redundant PETs, we would be 
able to identify approximately 80% of SVs that could be discovered by this technology (Figure. 
3.5). We calculated that using standard short tag sequencing strategies with 500 bp fragments; 
we would require 540 million non-redundant PET reads to match this threshold. Most of the 17 
genome datasets were either above or close to this mark, except that of 3 breast tumors (BT1, 
BT2, BT5) which had only 10 or 5 million non-redundant PET sequences for approximately only 
40-50% of SVs. In our later analyses, we noted that these three tumors showed under 
representation of SVs most likely due to the lack of comparable coverage. In order to 
discriminate the simple and complex SVs in each genome, supercluster analysis was done in 
each 17 genomes and all the SVs which had supercluster count ≥4 were identified as complex 
SVs (Figure 3.6).  
 66
 
Figure 3.4.  dPET cluster count distribution of 17 DNA-PET libraries. 
The number of observed dPET clusters (y-axis) is shown for the individual cluster counts (x-axis). Red 





                                                   Sequencing depth [# of total PETs] 
Figure 3.5. Saturation curve for breakpoint discovery. 
The total of all non-redundant PETs (x-axis) of MCF-7 was reduced in increments of 5% and plotted 




Figure 3.6. Connectivity of breakpoints in 17 DNA-PET libraries. 
(A) Interconnection network establishment. (B) Color code for c-s. (C-S) Distribution of degrees of connectivity for the indicated genomes (top 
right). Numbers of clusters (y-axis) for each supercluster size (number of interconnected clusters, x-axis) is shown.  
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          In total, we predicted 12,537 SVs in these 17 genomes (Table 3.3, Details in Appendix 
Table 4). Majority of them (n=11,394, 91%) were simplex SVs and only 9% (n=1,143) were 
complex SVs. Three genomes including MCF7, SKBR3 and TMK1 had most abundant complex 
SVs more than two hundred (Table 3.3). The genomes which had the complex SVs less than ten 
were Breast tumor 1, 2 and 5 and this might due to the lack of comparable coverage, because the 
three tumor samples had the lowest coverage among the 17 genomes. Deletion is the most 
predominant SV type (n=7,376; 59%), ranging from 131 deletions found in breast tumor 5 to 
1,027 in gastric tumor 28. Each the other SV types accounted for less than 10%. Among them, 
unpaired inversions (n=1,222, 9.7%), complex rearrangements (n=1,143, 9.1%), tandem 
duplications (n=1,033, 8.2%), and inversions (n=908, 7.2%) were considered at the same 
frequency level, whereas insertions (intra-chromosomal n=264, 2.1%; inter-chromosomal n=105, 
0.8%) were in lower frequency. We also detected a significant number of isolated inter-
chromosomal translocation events (n=482, 3.8%), but very few balanced translocations, one (2 
rearrangement points) in T47D and one in TMK1.  
        The span of the predicted SVs ranged from 402 bp to >216 Mb. One hundred and sixty-four 
deletions were predicted to have a size below 2 kb with the smallest of 402 bp. Since deletions 
are called based on the stretched mapping and this is dependent on the distribution of the insert 
size of a library, predicted deletions <2 kb are increased for false positives. One hundred and 
fifty-eight deletions were predicted to have a span >1 Mb with the largest of >216 Mb. It is 
possible that other events inside large SVs change the overall picture although the connectivity 
network established by the superclustering reduces the rate of misclassification of SVs by 
describing regions with many breakpoints as complex. The smallest predicted tandem 
duplication had the size of 1,132 bp, the largest was >127 Mb. The smallest predicted inversion  
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Table 3.3: Isolated and complex SVs in 17 DNA-PET libraries 
  

















Normal European 460 28 43 58 20 6 18 0 18 15 130 
African 189 25 38 64 16 0 14 0 2 8 72 
Breast tumor 
BT1 226 13 31 26 6 0 11 0 0 0 17 
BT2 280 40 32 38 10 6 13 2 2 5 35 
BT5 131 22 24 38 8 2 12 0 0 5 24 
BT13 682 39 85 38 22 6 34 0 33 18 61 
BT14 159 46 70 56 16 7* 22 0 40 18 57 
Breast cancer 
cell line 
MCF-7 352 203 83 60 14* 8 59 0 146 122 101 
SKBR3 606 78 135 56 14 6 45 0 158 47 68 
T47D 223 32 37 40 6 0 24 2 6 6 45 
Gastric 
tumor 
GT17 640 71 180 80 19* 14 77 0 32 13 141 
GT26 341 62 68 48 15* 4 28 0 6 14 40 
GT28 1027 29 38 62 16 6 14 0 31 15 106 




TMK1 571 103 183 76 27* 11* 48 2 150 82 233 
Other cancer 
cell lines 
HCT116 614 74 49 58 24 12 13 0 26 13 77 
K562 500 140 86 56 16 13* 36 0 73 19 92 
* one of the two clusters belong to another SV category
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was 996 bp, the largest >115 Mb. Insertions ranged from 1,165 bp to >77 Mb and unpaired 
inversions had a distance between the predicted breakpoints of 555 bp to >216 Mb. Overall, 
there is technically no upper size limitation to detect SVs by 10 kb insert DNA-PET. We did not 
undertake extensive efforts to evaluate the lower boundary to detect small deletions but the 
discovery rate is lower and false discovery rate higher for the deletions <2 kb. The lower size 
boundary for other SV categories is limited by our minimum anchor size requirement of 1 kb for 
10 kb DNA-PET libraries and 500 bp for the 5 kb library (Breast tumor 13).  
        Interestingly, the median cluster count of the 17 genomes were higher for deletions (median 
= 11) and inversions (median = 13) compared to the cluster count of the other SVs (medians 
ranging from five to eight; Figure 3.7). Unpaired inversions showed the lowest median cluster 
size of five. The larger median cluster size of deletions correlated with a higher PCR validation 
rate (see below) and was mainly due to deletions smaller than 10 kb. Inversions had a high rate 
of repeated observations across the 17 genomes which increases the confidence and also 
indicates that many inversions are of high frequency. High frequency events are more likely to 
be in a homozygous state which will result in a larger cluster size than heterozygous events. 
Rearrangement points of somatic events, if not amplified, are expected to be at a lower copy 
number per tissue sample than a homozygous germline SV due to heterogeneity across cells 
within a tumor. We investigated the median cluster size of the tumor samples vs. the normal 
samples and cell lines and indeed found a trend of lower cluster sizes for tumor SVs compared to 








































































































































































































































































































Figure 3.7. Median of SV specific dPET cluster counts for 17 DNA-PET libraries. 
SV categories are shown on the x-axis, and the median of the dPET cluster count for each genome is 
shown on the y-axis. Thick horizontal lines indicate median, boxes represent values of libraries from the 
25th to 75th percentile, whiskers indicate minimum and maximum, and circles indicate outliers. (A) Box 
plots of 17 genomes; (B) box plots of 17 genomes divided into cell lines and normals (n=9) and tumors 
(n=9). 
 
Collectively, the concordant and discordant DNA-PET mapping data constitute the 
comprehensive SV map for each cancer and normal genome (Figure 3.8), displaying the precise 
genome architecture and quantitative measurements of copy number variations. For example, the 
SV map of K562 showed the accurate position of the known BCR-ABL1 translocation between 
chromosome 9 and 22 (Daley et al. 1990; Groffen et al. 1984; Heisterkamp et al. 1990), and the 
previously reported BCAS3-BCAS4 fusion between chromosome 17 and 20 in MCF-7 (Ruan et al. 
2007). The two breast cancer cell lines SKBR3 and MCF-7 showed the most extreme 
amplification hotspots for inter-chromosomal rearrangements (e.g. between chromosomes 8, 14 
and 17 in SKBR3 and chromosomes 3, 17 and 20 in MCF-7).  
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Figure 3.8. Karyo-genomic maps of 15 cancer and 2 normal human genomes. 
Genomes are arranged in a circular manner with SV-categories arranged in concentric layers as indicated 
on the top left. Circular plots have been generated using Circos (Krzywinski et al. 2009). 
 
Copy number analysis by cPET 
The whole genome copy number analysis by cPET showed that approximately 0.1% of the 
normal genomes had an estimated copy number >4, therefore, we defined >4 copies as high copy 
regions. Regions with an estimated copy number <1 were defined as low copy regions which 
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included homozygous- and high confidence heterozygous deletions (ca. 0.3% of the normal 
genomes had <1 copy). We subtracted the regions with high and low copy number, respectively, 
in the normal genomes (which were likely to be copy number variations [CNVs]) from the 
cancer genomes (Figure 3.9-3.10). As expected, there were less high copy regions in the five 
breast and four gastric primary tumors (a total of 1.6 and 12.8 Mb, respectively) compared to 
breast cancer and gastric cancer cell lines (a total of 86.6 and 86.4 Mb, respectively). SKBR3 
displayed five regions on chromosome 8 totaling 11 Mb, and a 12.8 Mb region on chromosome 
19 with a copy number just below 1, suggesting a heterozygous deleted state.  
        We compared high and low copy regions across our eight breast cancer and five gastric 
cancer genomes (Figure 3.11 and Appendix Tables 5-8). There were 599 loci with an estimated 
copy number >4 in the breast cancer samples. Four hundred and thirty-five (72.6%) of these 
regions spanned genes and 101 (24.4%) of the gene-spanning amplified loci were identified in 
more than one breast cancer sample. We also identified 69 loci with copy number <1 in at least 
one out of eight breast cancer genomes. Forty-eight (69.6%) of these loci spanned genes and five 
(10.4%) of the gene spanning low copy loci were identified in more than one genome (Figure 
3.11). Similarly, we obtained 24 recurrent high copy and 10 recurrent low copy regions 
containing at least one gene among the five gastric cancer genomes. It is most likely that cancer-





Figure 3.9. Genomic regions of high copy number in 15 cancer genomes. 
Chromosomes are represented by horizontal lines and regions with more than two consecutive windows 
with a copy number >4 are indicated by colored bars. Regions showing amplification in at least one of the 
two normal genomes which match amplified regions in the cancer genomes by >50% have been excluded. 
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Figure 3.10. Genomic regions of low copy number in 15 cancer genomes. 
Chromosomes are represented by horizontal lines and regions with more than two consecutive windows 
with a copy number <1 are indicated by colored bars. Regions showing low copy number in at least one 





Figure 3.11. Overlap of amplified and deleted regions breast and gastric cancer genomes. 
Overlap of amplified and deleted regions in eight breast cancer (A) and five gastric cancer genomes (B). 
Genomic regions with a predicted copy number >4 are represented in red, regions with a predicted copy 
number <1 are represented in green. The number of genomes in which the same region was observed is 
represented on the x-axis. High/low copy regions which matched high/low copy regions observed in at 








Copy number support for deletions and tandem duplications 
As tandem duplications and deletions (if not reciprocal) are expected to result in copy number 
changes, we tested this by using the sequence tag based copy number approach with a copy 
number change of  ≥0.5 in the expected directions at the predicted breakpoints. Using these 
criteria, average 52% of the deletions and 14% of the tandem duplications matched with copy 
number decrease and increase, respectively (Table 3.4). The relatively low fraction of deletions 
and tandem duplications with copy number support is partly attributable to the fact that the copy 
number estimation is based on cPET tags. Windows which overlapped with dPETs were omitted 
from the copy number analysis, and this affected in particular small deletions and tandem 
duplications. Small tandem duplications are more sensitive to this phenomenon than deletions, 
since their dPET anchor regions are inside of the tandem duplication when mapped to the 











Table 3.4 Deletions and tandem duplications with copy number support in each genome 
 Deletion Tandem duplication 
European 265 4 
African 107 3 
Breast tumor 1 121 0 
Breast tumor 2 176 7 
Breast tumor 5 58 3 
Breast tumor 13 294 4 
Breast tumor 14 78 2 
MCF-7 201 49 
SKBR3 336 28 
T47D 165 5 
Gastric tumor 17 197 1 
Gastric tumor 26 173 9 
Gastric tumor 28 257 2 
Gastric tumor 38 197 3 
TMK1 357 31 
HCT116 306 19 
K562 305 13 
 
Characteristics of SVs in cancer genomes 
The structural maps of the 17 genomes should include germ line and somatic SVs, as well as 
mapping artifacts and assembly errors in the reference genome sequence. We reasoned that if a 
particular SV was shared among all 17 genomes, this would most likely represent a rare allele or 
an assembly error in the reference genome. If an SV was observed in multiple, but not all, 
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genomes, it would most possibly represent a germ line SV that was accumulated in human 
populations through evolution history. In contrast, if a SV was unique to one particular cancer 
genome, then it might be considered as derived somatically. Thus, we conducted comparative 
analysis of all SVs identified by dPET mapping in the 17 genomes, and found 57 different SVs 
that were common in at least 16 of the 17 genomes (Figure 3.12 and Appendix Table 9); 1,290 
SVs that were shared by multiple genomes (2-15 genomes; Appendix Table 10), indicating 
potential “germ line” origin; 4,527 SVs which were unique to single genomes (Appendix Table 
11), of which 4,489 SVs were found only in cancer genomes and which we considered as, most 
likely, “somatic” events. The median fraction of uniquely observed SVs in the 15 cancer 
genomes was 26.3% compared to 7.2% in 16 normal genomes (including DNA-PET data of 14 
additional normal genomes; p=4.46 x 10-7; Figure 3.13) suggesting that a large fraction (1-





Figure 3.12. Predicted SVs that were observed in 16 or 17 out of 17 genomes by dPET clusters. 
(A) SV categories of the 57 dPET clusters observed in 16 or 17 genomes. Deletions and inversions are the 
predominant SV categories. (B) Example of a deletion. The predicted deletion matches entries reported by 
Korbel et al. (Korbel et al. 2007) downloaded from the Database of Genomic Variants (DGV, Iafrate et al. 
2004) by 94%. Red track represents the coverage of the cPETs, blue track represents the average span 
between the two tags of a PET. Dark red and pink arrows connected by a green line represent the left and 
right anchor region, respectively, flanking the deletion. Horizontal lines (bottom) represent SV entries in 
DGV. (C) Example of an inversion. Black box indicates inverted segment. The cPET coverage drops 
down to zero at the predicted breakpoints, suggesting a homozygous genotype. (D) Intra-chromosomal 
inverted insertion of 21 Kb on chromosome 11. The combination of a deletion with an inverted insertion 
demonstrates the cut (black box) and paste (black arrow) nature of the deletion. Previously reported 




Figure 3.13. Unique vs. multiple observations of SVs identified by DNA-PET sequencing. 
 SVs of 2 normals of this study (Normal 15 and 16), 14 additional normals (unpublished data) and 15 
cancer genomes (x-axis) were compared with each other and with the published SVs of 10 normal 
genomes (Kidd et al. 2008; Korbel et al. 2007). SVs that were observed only in one genome (unique) are 
shown in light red and SVs observed in two or more genomes are in dark red. Proportions of uniquely and 
multiple observed SVs are given on the y-axis. Dashed lines indicate median of uniquely observed SVs in 
normal and cancer genomes, respectively.  
 
        The PCR validation rate for multiply observed SVs was higher than the rate for uniquely 
observed SVs (78.4% vs. 69.2%, respectively), indicating a higher false discovery rate for the 
unique category. Among the 17 genomes, we found 62 and 96 unique SVs, respectively, in the 
normal genomes which could represent novel private germ line SVs. We also found an average 
unique SVs of 115 in breast tumors (range: 43-306), 344 in gastric tumors (range: 73-669), 428 
in breast cancer cell lines (range: 104-651), and 584 in the single gastric cancer cell line, TMK1. 
Although the comparison of the European and African normal samples with European (breast 
tumors) and East-Asian (gastric tumor) cancer samples is not straightforward, the increase of 
unique SVs in primary tumors and cell lines can be explained by somatic rearrangements. Some 
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SV classes appear to be more likely germ-line variants than others. Most inversions and intra-
chromosomal insertions found in the 17 genomes were highly shared among multiple genomes 
and were significantly represented in the two normal genomes, suggesting that the majority of 
SVs in these two categories are most likely of “germ line” origin (Figure. 3.14). Most of the 
isolated deletions and inter-chromosomal insertions could also be considered as “germ line” SVs. 
In contrast, tandem duplications, isolated translocations, unpaired inversions, and complex 






Figure 3.14. Comparison of SVs across 15 cancer and 2 normal genomes. 
(A–H) Frequencies (y-axis) of the indicated SV categories are shown for the individual genomes (x-axis). 
Cancer groups are separated by vertical gray lines. Degree of recurrent observation of the same SV is 
indicated in (I) where 1 represents the observation in one genome and 17 represents the observation in all 
17 genomes. (J) SVs which were observed in the normal individual(s) or which were observed in the 
cancer genomes but match those observed in the normal individuals or match by >80% earlier described 
events (Kidd et al. 2008; Korbel et al. 2007) are indicated in dark blue. SVs which were also observed in 
other 14 normal individuals are indicated in light blue. SVs observed only in cancer genomes are 
indicated in orange. The x-axis represents the number of genomes which share a particular SV and y-axis 
represents the frequency.  
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        As no DNA samples of paired non-cancer (normal) tissues were available for the 15 cancer 
genomes, we used the SVs identified in 12 unrelated normal individuals, two of this study and 10 
published previously (Kidd et al. 2008; Korbel et al. 2007), to filter and thereby strongly enrich 
the set of  cancer SVs for somatic events. Since the aim of this project was to analyze the general 
characteristics of genome structural changes in breast and gastric cancer, the strong enrichment 
for somatic events was considered sufficient. Using the common SV filtering approach, we 
classified the SVs of the 15 cancer genomes that were sheared with normal genomes in this study 
or in previous reports (Kidd et al. 2008; Korbel et al. 2007) as “normal genome SVs” (n = 5,105, 
Figure 3.15), and the SVs found only in at least one of the 15 cancer genomes but not 
represented in normal genomes as “cancer genome SVs” (n = 6,410, Figure 3.15). Most cancer 
SVs (87.3%) were identified only in one genome, whereas normal SVs were mostly shared by 
multiple genomes (Figure 3.16). This suggests that most cancer specific SVs are likely to be 




Figure 3.15. Flow chart of dPET cluster data.  
The rearrangement points include redundant observations in different genomes. 
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Figure 3.16. Numbers of observed SVs across 17 human genomes analyzed by PET sequencing. 
Note the high proportion of uniquely observed SVs in the cancer genomes compared to the normal European. The normal African genome also 
shows a high proportion of uniquely observed SVs. This may be due to differences in ethnicity since the breast cancer tumors and cell lines are 
derived from European and gastric cancer tumors from Asian individuals. 
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        To evaluate the efficiency of our common SV filtering approach, we analyzed the DNA-
PET data of a tumor/blood pair and compared our filtering approach with the matched pair 
filtering. Of 1,144 SVs identified in the tumor, 716 were classified as tumor specific SVs using 
the common SV filtering approach whereof 236 were detected in the paired blood sample of the 
tumor indicating their germ line origin (Figure. 3.17). This resulted in 67% (480/716) of the SVs 
which were assigned as tumor specific by the common filtering that were also assigned as tumor 
specific using the DNA-PET information of the paired blood sample. The cancer SVs were 











       Figure 3.17. Comparison of germ line variation filtering by a paired sample approach vs. the        
       common SVs approach and validation of somatic SVs. 
 
(A) SVs of a tumor (green) and the matched (normal) blood (pink) were intersected with each other and 
with SVs identified in the two normal individuals of this study and published SVs of ten normal 
individuals (Kidd et al. 2008; Korbel et al. 2007), respectively (purple). The numbers of SVs are indicated 
for each category and section of the diagram. Seven hundred and sixteen SVs (236+480) were classified 
as cancer SVs by the common SV filtering of which 236 SVs (33%) were of germ line origin based on the 
paired sample. This fraction further drops by increasing the pool of normal samples. Four hundred eighty 
SVs were identified as somatic mutations by the combined filtering approach, includes redundant SVs in 
different individuals. (B) PCR validation of predicted somatic SVs in (A). Primer pairs flanking 16 
somatic rearrangement points predicted by DNA-PET were used to PCR amplify potential rearrangement 
points with DNA templates from the normal blood (N) and tumor (T), respectively. PCR products were 
separated together with a molecular size marker (M) by electrophoresis in 1% agarose gels and stained by 
ethidium bromide. Reactions of 15 out of 16 predicted somatic rearrangement points resulted in specific 
PCR amplicons in the tumor but not in normal samples. The positive control PCR reactions from a 
genomic location of a germ line SV show comparable input DNA templates and PCR efficiency for the 
tumor and normal samples. 
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        Although the number of breast and gastric cancer samples in our study was limited, we 
attempted to identify potential recurrent rearrangements. In the comparative analysis, we 
observed 244 cancer SVs in more than one breast cancer and 256 cancer SVs in more than one 
gastric cancer genome. After further filtering by additional SVs of 14 normal individuals mapped 
by DNA-PET (unpublished data) and overlap (>50%) with entries in the Database of Genomic 
Variants (DGV) (Iafrate et al. 2004), we identified 15 potentially recurrent SVs in breast cancers, 
and 21 in gastric cancers (Table 3.5). Since we expect different breakpoints as a genuine 
criterion for a recurrent event in two different genomes, we analyzed the breakpoints by PCR and 
Sanger sequencing. The majority of the potentially recurrent events showed exactly the same 
breakpoints or could not be validated (27/36). The remaining events, four in breast cancer and 
five in gastric cancer (Appendix Table 12), had highly homologous sequence features in the 
breakpoint junction regions, so that the exact breakpoint positions could not be precisely 
determined by this method. Among them might be some real recurrent events. All except one are 
intra-chromosomal and six out of nine are alterations shorter than 25 kb. Many of them have the 
potential to alter gene functions, either in coding sequences (deletion of exons or altering introns 
in 3/9) or in regulatory regions (3/9). However, none of the putative recurrent SVs represent 
putative fusion transcripts. Further investigation of the breakpoint characteristics and analysis in 
larger cohorts of tumor specimens and in normal DNA will be necessary to distinguish recurrent 






Table 3.5 Effect of in silico filtering of potentially recurrent breast and gastric cancer 
      breakpoints: most cancer breakpoints are uniquely observed 
 
Cancer Type Total percent % of remaining breakpoints after filtering by 
   Additional normal genomes1) DGV2) 
Breast Uniquely observed 100 (n=2,078) 83.7 (n=1,739) 80.8 (n=1,680) 
 Potentially recurrent 100 (n=244) 15.2 (n=37) 6.1 (n=15) 
Gastric Uniquely observed 100 (n=2,135) 84.1 (n=1,795) 80.7 (n=1,723) 
 Potentially recurrent 100 (n=256) 8.6 (n=22) 8.2 (n=21) 
1) 14 additional normal genomes analyzed by paired-end sequencing (unpublished data) 
2)
 Entries in the Database of Genomic Variants which match by ≥50% 
 
        We further compared the breast cancer SVs identified in this study with SVs identified in 
the 24 breast cancer genomes sequencing paper (Stephens et al. 2009).Twenty different SVs 
overlapped by >50% with SVs identified in our study (Table 3.6). Most of them were large 
rearrangements on chromosome 8 in MCF-7 and SKBR3, respectively. A homozygous deletion 
of 170 kb on chromosome 9 (21,809,532-21,979,622) in MCF-7, which deletes the tumor 
suppressor gene CDKN2A, overlaps by 70% with a deletion reported by Stephens and colleagues 
(Stephens et al. 2009). CDKN2A is a tumor suppressor gene and homozygous or heterozygous 
deletions of CDKN2A in breast cancer and other cancer had been reported earlier (Jonsson et al. 
2007) which confirm the relevance of this locus for breast cancer. 
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Table 3.6 Breast cancer specific rearrangements which overlap by ≥50% with events reported by Stephens et al. (2009) 
Genome SV type Coordinates 
Cluster 












MCF-7 Deletion chr7:69635775..69861732 18 255,957  AUTS2 0 Deletion 68 
SKBR3 Deletion chr8:89529429..425352316 4 35,822,887   133 Amplified 57 
SKBR3 Deletion chr8:92619012..109850006 132 17,230,994 TMEM74  76 Deletion 68 
MCF-7 Deletion chr8:106854866..124772942 18 17,918,076 ZFPM2,ANXA13  49 Amplified 85 
SKBR3 Complex intra-chr. chr8:108941884..133280776 15 24,338,892 KCNQ3  n.a. Amplified 64 
SKBR3 Deletion chr8:110109746..112776734 66 2,666,988   14 Amplified 57 
MCF-7 Deletion chr8:112436691..121631999 46 9,195,308 SNTB1  21 Amplified 63 
SKBR3 
Tandem 
duplication chr8:89760331..112880172 7 23,119,841   95 Amplified 53 
SKBR3 Deletion chr8:114510462..121971682 70 7,461,220 CSMD3  21 Amplified 51 
SKBR3 
Tandem 
duplication chr8:91601813..114532206 25 22,930,393   91 Amplified 53 
SKBR3 Deletion chr8:115867498..127928991 3 12,061,493   50 Amplified 77 
SKBR3 Deletion chr8:115872706..123915028 5 8,042,322 ZHX2  23 Amplified 84 
SKBR3 Complex intra-chr. chr8:120588540..142127407 13 21,538,867   n.a. Amplified 60 
SKBR3 Deletion chr8:120938433..141865475 21 20,927,042 PTK2  67 Amplified 62 
SKBR3 
Tandem 
duplication chr8:88485220..123034720 8 34,549,500   121 Amplified 59 
SKBR3 Complex intra-chr. chr8:118044568..124227138 9 6,182,570 WDR67,SLC30A8  n.a. Amplified 64 
SKBR3 Complex intra-chr. chr8:128999924..132263367 16 3,263,443 PVT1  n.a. Amplified 50 
MCF-7 Deletion chr8:129972165..132903766 48 2,931,601   5 Amplified 63 
MCF-7 Deletion chr9:21809087..21979717 14 170,630 MTAP,CDKN2A  2 Deletion 70 
MCF-7 
Tandem 




 % of overlap between events identified in this study and in the study by Stephens et al. (2009)
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        We also investigated whether the segmental size of SVs involved in cancer genomes has 
some specific characteristics. Interestingly, the sizes of tandem duplications of breast and gastric 
cancers were clearly larger than those found in normal genomes (median tandem duplication size 
in normals =22 kb vs. 100 kb in breast cancer cell lines [p=8x10-6], 143 kb in gastric tumors 
[p=4.5x10-4], and 91 kb in TMK1 [p=5x10-4]; Figure. 3.18). The size of unpaired inversions was 
also larger than that of other SV categories. Compared to normal genomes, the size of unpaired 
inversions was significantly larger in breast cancer cell lines (p=0.007). Inversions and insertions 












Figure 3.18. Distance of breakpoints. 
 
(A) Median sizes of different SV categories. SVs were grouped into seven categories: two normal individuals, five breast cancer tumors, three 
breast cancer cell lines, four gastric cancer tumors, TMK1, HCT116 and K562. Of all cancer data sets, SVs which matched those observed in the 
normal individuals were excluded. Mann-Whitney U test P values <0.01 compared to normal SV sizes are displayed: *, P<0.01; **, P<0.001; ***, 
P<0.0001. (B) Size distribution of tandem duplications indicates an overrepresentation of size 100-300 Kb (shaded in gray) in the cancer 
categories relative to normal. SVs were grouped as described in (A).  
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Characteristics of breakpoints 
We were interested in understanding whether SVs of potential somatic origin in cancer genomes 
(identified only in cancer after subtracting normal SVs) have distinctive features around the 
break points that would provide insights for the underlying mechanisms of cancer genome 
rearrangements. The set of 12,537 SVs identified in this study has a median resolution of <400 
bp, based on the comparison of the DNA-PET predicted breakpoint coordinates with PCR and 
Sanger sequencing determined breakpoint coordinates. One thousand and twenty-two of the SVs 
were likely to be normal variants, and 6,410 were likely to be cancer associated (Figure. 3.15). 
This pool of precise SVs represents an unprecedented resource for the determination of sequence 
features associated with rearrangement events.  
         Overall, we have observed that significantly more normal SVs (from germ line DNA) had 
breakpoint sequence homology than cancer SVs, with striking differences for tandem 
duplications, unpaired inversions, and complex rearrangements: ~60% of the normal category 
had breakpoint homology as compared to ~20% of the cancer category (Figure 3.19.A, p<10-15). 
This result suggests that non-homology-based rearrangements are characteristic for cancer 
genomes, which is in accordance with the understanding that a significant proportion of normal 
SVs is mediated by nonallelic homologous recombination (NAHR), whereas the majority of 
somatic events in rearranged cancer genomes is based on non-homologous end-joining (NHEJ) 
(Hampton et al. 2009; Raphael et al. 2008). At the level of specific SV types, among the normal 
SVs, deletions showed the lowest fraction of breakpoint sequence homology (24.9%) and inter- 
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chromosomal insertions showed the highest fraction (90.9%). 
 
Figure 3.19. Sequence features of rearrangement points. 
(A) Normal and cancer SVs were stratified for the presence or absence of sequence homology between the two 
breakpoints of a pair. (B) Sequence features for SVs with sequence homology. SD, segmental duplication; L1, long 
interspersed nuclear element 1; Alu, Alu element; other, other UCSC annotated multi copy sequences. (C-G) 
Cumulative alignment of sequence homologies at predicted breakpoints (vertical dashed lines). Blue lines indicate 
sequence homologies between the same strand of genomic DNA, red lines indicate sequence homologies between 
different strands. (C-F) Middle, schematic representations of genomic regions. Boxes indicate regions between 
breakpoints; arrows indicate orientation of sequence homology. Bottom, schematic representation of recombination 
mechanisms. Blue “X” indicates locus of recombination. (H) Micro-homology of sequenced breakpoint pairs. (I) 
Insertions of DNA sequences of unknown origin for breakpoint pairs without micro-homology. 
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Segmental duplications were the major source for sequence homology of all SV types and 
account for all homologies of normal inter-chromosomal insertions (Figure 3.19.B). In cancer 
SVs, tandem duplications and complex rearrangements had the least homology, followed by 
deletions and isolated translocations.  
        We further investigated the location and orientation of the homologous breakpoint 
sequences, and found that the homologous sequences of deletions and tandem duplications were 
positioned in tandem orientation (head to tail or on the same strand), whereas for inversions and 
unpaired inversions, the two homologous sequences were positioned in reverse orientation (head-
to-head or on different strands, Figure 3.19. C-F). The specific orientation of homology, which is 
in accordance with the assumed DNA looping structures, demonstrates that the underlying 
mechanism is NAHR (reviewed in (Gu et al. 2008). Interestingly, we observed increased 
frequency of sequence homology at the predicted breakpoints for deletions (n=910) and in 
particular for inversions (n=160) with a higher frequency of sequence similarity at the predicted 
breakpoint inwards of the anchor regions (Figure 3.19. C-D). In contrast, the homologous 
sequences at the breakpoints of unpaired inversions (n=203) showed relatively even distributions 
on both sides of the breakpoints, indicating that the breakpoint/homology correlation is less 
specific (Figure 3.19. F). These deposition patterns of homologous sequences suggest a 
distinctive DNA alignment mechanism for inversions as compared to unpaired inversions. We 
also observed a moderate difference in alignment profiles between deletions and tandem 
duplications (n=149). Other SVs such as insertions (n=194), isolated translocations (n=73), and 
complex events (n=172) showed less characteristic patterns, suggesting other underlying 
mechanisms (Figure 3.19. G).  
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        For SVs that had no significant homology (BLAST score <300), we conducted detailed 
analysis of the junctions by PCR and sequencing to investigate the frequency of possible micro-
homology, a reported signature of NHEJ (Cahill et al. 2006). We did not observe general 
differences in the micro-homology rates between cancer and normal SVs (Figure 3.19. H-I and 
Appendix Table 13). Deletions (cancer and normal) showed the lowest degree of micro-
homology which might suggest a mechanism without open DNA-end intermediates. 
The impact of SVs on genes 
We investigated whether more gene structures were altered in the cancer genomes compared to 
the two normal genomes. Since the majority of the SVs which were enriched in the cancer 
genomes were uniquely observed (Figure 3.14. J), we compared the numbers of genes which 
were affected by genome-unique breakpoints. Two breast tumors, two gastric tumors and all cell 
lines showed a larger number of genes which were predicted to be fused compared to the two 
normal genomes (Figure 3.20. A), with MCF-7 showing the largest number of predicted fusion 
genes (n=52). A similar pattern was observed for truncated genes with an additional gastric 
tumor showing a high number of affected genes (Figure 3.20. B). We observed the largest 
number of genes with deletions inside their gene bodies for gastric tumor 28 followed by breast 
tumor 13, which correlates with the largest numbers of small deletions (<4 Kb) in these genomes 
(324 and 244, respectively; Figure 3.20. C). The number of genes in amplified regions (copy 
number >4) was higher for all cell lines except HCT116 compared to the two normal genomes, 
with SKBR3 having the largest number of 845 genes (Figure 3.20. D). The data reflect a 
quantitative difference of genes affected by structural changes for most of the sufficiently 
sequenced cancer genomes with the same trend in breast and gastric cancer. Cell lines show 
more genes which are fused, truncated or in amplifications compared to primary tumors. A 
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detailed analysis of the impact of the genomic rearrangements on the transcriptome of the eight 
breast cancer samples is provided elsewhere (Inaki et al. 2011). 
 
Figure 3.20 Genes affected by SVs. 
Number of fusion genes (A), truncated genes (B), and genes with deletions inside their gene bodies (C) 
which are predicted by uniquely observed breakpoints. (D) Genes in regions with predicted copy 
numbers >4.  
 
Whereas breakpoints in normal genomes occurred as frequently in gene deserts as in 
other regions, cancer breakpoints were significantly under-represented in gene deserts compared 
to expectation (p<10-15; Figure 3.21). Intriguingly, we found that cancer breakpoints were not 
enriched within gene bodies but within 10 kb up- and downstream of genes (p<10-15). Taken 
together, these data suggest that perturbation of gene regulation may be under positive selection 
in the evolution of a cancer cell.  
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Figure 3.21. Observation of breakpoints relative to genes.  
Breakpoints were split in seven categories: normal individuals (n=2), breast cancer tumors (n=5), breast 
cancer cell lines (n=3), gastric cancer tumors (n=4), and the cell lines TMK1, HCT116, and K562. Of all 
cancer data sets, breakpoints which matched SVs observed in the normal individuals were excluded. Gene 
deserts were defined as 1 Mb regions without gene annotation (RefSeq +10 kb). The proportion of gene 
deserts vs. the rest of the genome was taken as the expected proportion of breakpoints and compared with 
the observed number of breakpoints. Similarly, 10 kb regions up- and downstream of gene and RefSeq 
genes, respectively, were analyzed. *, P<0.05; **, P<0.01; ***, P<10-4; ****, P<10-5; *****, P<10-10 Chi2 
test. Statistics for individual genomes show the same trend. 
 
        Small deletions, tandem duplications and insertions within genes can affect transcripts by 
deleting, duplicating or inserting exons or altering splicing. In particular, we have validated on 
the genomic and transcription level in MCF-7 a 53.6 kb deletion in ITPR1 resulting in an in-
frame deletion of exons 42-57 (Figure 3.22). Partial deletions and a missense mutation of the 
inositol triphosphate receptor type I gene (ITPR1) have been reported to be responsible for 




Figure 3.22. Deletion of 15 exons of ITPR1 in MCF-7. 
Genome Browser screen shot of the ITPR1 locus in MCF-7 (top) shows cPET coverage track (red) and a 
deletion (dark red and pink arrows). Genomic breakpoints have been validated by PCR and Sanger 
sequencing. Gene structure derived from breakpoints and RT-PCR is shown below. Bottom: RT-PCR and 
sequencing result confirms the deletion of exons 42-57.  
 
        Gene ontology (GO) analysis of all genes with breakpoints showed cell adhesion-mediated 
signaling and cell adhesion as the two most significantly overrepresented gene categories in 
breast and gastric cancer (Table 3.7). This is in accordance with the understanding that epithelial 
cancers frequently show aberrations in cell-cell and cell-extracellular matrix interactions. 
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Table 3.7 Gene ontology (GO) analysis of genes1) with breakpoints in breast and gastric cancer genomes 
Breast cancer  Gastric cancer 
Biological Process2) RefGene Expected Observed +/- P value     RefGene Expected Observed +/- P value 
Cell adhesion-mediated signaling 386 20.88 51 + 2.22E-06  Cell adhesion 592 31.61 73 + 2.62E-09 
Cell adhesion 592 32.02 65 + 3.47E-06  Cell adhesion-mediated signaling 386 20.61 49 + 9.66E-06 
Neuronal activities 561 30.34 54 + 1.52E-03  Signal transduction 3256 173.84 222 + 1.53E-03 
Biological process unclassified 5972 322.97 269 - 3.04E-03  Synaptic transmission 275 14.68 33 + 3.24E-03 
Electron transport 230 12.44 2 - 1.05E-02  Cell communication 1207 64.44 98 + 4.47E-03 
Other intracellular signaling 
cascade 
212 11.47 27 + 1.12E-02  Neuronal activities 561 29.95 51 + 6.94E-03 
Cell communication 1207 65.28 97 + 1.16E-02  Biological process unclassified 5972 318.84 273 - 2.36E-02 
Chemosensory perception 204 11.03 1 - 2.67E-02  Chemosensory perception 204 10.89 1 - 3.04E-02 
Developmental processes 2065 111.68 144 + 2.97E-02          
1) Genes with breakpoints are all genes which have a breakpoint in at least one out of eight breast cancer and one out of five gastric cancer genomes, respectively. Breakpoints 
which matched those observed in the normal individuals were excluded.  
2) GO analysis was performed using Panther (www.pantherdb.org) with RefSeq genes downloaded from UCSC (http://genome.ucsc.edu/) as reference. “Unclassified” biological 
process (n=1 for each list of biological processes) has been excluded.  
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Genomic architecture of amplified regions in MCF-7 
A hallmark of cancer genomes is the complex amplification of DNA segments (Hicks et al. 
2006; Jonsson et al. 2007). This is evident in the 15 structural maps of cancer genomes 
(Figure. 3.6). Indeed, amplifications and inter-chromosomal translocations were observed in 
both primary tumors and cancer cell lines. The MCF-7 genome has been extensively studied 
by targeted sequencing analyses of the amplified regions (Hampton et al. 2009; Raphael et al. 
2008; Volik et al. 2006) that have revealed complicated sequence structures. By comparing 
our data with these earlier findings, we found support for all four reported rearrangement 
points at the ZNF217 locus (in BAC clone MCF7_1-3F5, (Volik et al. 2006) in the DNA-PET 
data with the breakpoint coordinates: 1) chr3:-63,998,040/chr20:-52,304,837 (predicted), 2) 
chr20:+40,267,945/chr20:+ 52,300,747 (predicted), 3) chr20:-40,249,066/chr20:+55,251,653 
(predicted), 4) chr20:+55,288,450/chr20:+51,615,194 (PCR validated). To compare our data 
with 35 rearrangements which have been resolved to the base pair level by Raphael and 
colleagues (Raphael et al. 2008), we searched for DNA-PET predicted rearrangement points 
which were within the maximum cPET span of the MCF-7 library (16,217 bp). We found 
support for 31 out of 35 rearrangement points (Appendix Table 14), of which 15 did not meet 
our quality criteria (six had a cluster size 2, nine had an anchor span <1000 bp).  
        Up to now, it is still not clear what events trigger the amplification cascades in cancer 
genomes. In MCF-7, 26% (268/1047, Table. 3.3) of the rearrangement points were inter-
connected into only six highly complex units. The largest of these units involved 205 dPET 
clusters (Figure. 3.4), including mixed types of mapping patterns, with an overrepresentation 
of tandem duplications, unpaired inversions, and inter- chromosomal translocations, which 
were tightly associated with the amplified regions on chromosomes 1, 3, 17, and 20 (Figure 
3.23. A). In this complex unit, the SV with the highest dPET cluster count (n=1,176) was 
mapped to a highly amplified region on 20q13, representing a tandem duplication of a large 
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fragment (3.67 Mb) at position 51-55 Mb (Figure 3.23. B). Double-probed DNA-FISH 
experiments validated this rearrangement, and the extensive FISH signals of the mixed 
probes in linear position and in multiple chromosomal locations indicated that the junction 
region of this tandem duplication was further multiplied locally as well as dispatched to other 
chromosomal locations (Figure 3.23. D-F). Thus, this junction appeared as an epicenter for 
subordinate dPET clusters that were connected to other parts of the genome, either intra- or 
inter-chromosomally.  The dEPT clusters to the left and right of the initial tandem duplication 
junction were smaller in size than the initial event, but their sum on each side was 
comparable to the cluster size of the initial event. An inter-chromosomal dPET cluster with 
498 dPETs connected chromosome 20 at 55 Mb (left side of the tandem duplication junction 
in Figure 3.23. C and G) to chromosome 17, while another inter-chromosomal dPET cluster 
with 370 dPETs connected chromosome 20 at 53 Mb (right side of the tandem duplication 
junction) to chromosome 17. As the number of dPETs of these two clusters were similar, it is  
conceivable that the two clusters represent the paired rearrangement points of an inter- 
chromosomal translocations, which were tightly associated with the amplified regions on 
chromosomes 1, 3, 17, and 20 (Figure 3.23. A). 
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Figure 3.23. Architecture and genealogy of amplifications in MCF-7. 
(A) Copy number plots of chromosomes 1, 3, 17, and 20 with amplified regions (red boxes). (B) 
Concordant tag distributions are shown for amplified genomic regions (top, green track). Genomic 
segments between predicted breakpoints are indicated by colored arrows (middle) and dPET clusters 
with cluster sizes greater than 140 are represented by horizontal lines flanked by dark red and pink 
arrows indicating 5’ and 3’ anchor regions (bottom). Small to large dPET clusters are arranged from 
top to bottom. All but three dPET clusters were classified as complex. Mapping characteristics are 
described by: Del, deletion; IT, isolated translocation; UI, unpaired inversion; TD, tandem duplication. 
Cluster sizes are given for each cluster. (C) Possible genealogy of amplification. TD1,176 occurred 
early and subsequent rearrangements have pasted TD1,176 in different genomic contexts (G). (D-F) 
Double-color FISH using probes flanking TD1,176. Red, chr20:51,920,860-52,096,191; green, 
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chr20:55,137,293-55,311,637. Double signals (filled arrow heads) indicate the fusion of the two loci 
and single signals indicate the normal genomic distance (open arrow head). (D) Metaphase 
chromosomes, (E) metaphase nucleus and (F) interphase nucleus showing amplification and fusion of 
breakpoint flanking sequences. (H) BMP7 (left) and ZNF217 (right) are juxtaposed by the TD 1,176 
rearrangement in a distance of 15,159 bp. (I) Models of local and inter-chromosomal amplification. 
Chromosomes are represented by gray and green horizontal lines. Amplified segment is represented 
by red arrow. The initial tandem duplication (left) allows local amplification between two sister 
chromatids or homologous chromosomes (top) or inter-chromosomal translocation (bottom).  
 
In this complex unit, the SV with the highest dPET cluster count (n=1,176) was mapped to a 
highly amplified region on 20q13, representing a tandem duplication of a large fragment 
(3.67 Mb) at position 51-55 Mb (Figure 3.23. B). Double-probed DNA-FISH experiments 
validated this rearrangement, and the extensive FISH signals of the mixed probes in linear 
position and in multiple chromosomal locations indicated that the junction region of this 
tandem duplication was further multiplied locally as well as dispatched to other chromosomal 
locations (Figure 3.23. D-F). Thus, this junction appeared as an epicenter for subordinate 
dPET clusters that were connected to other parts of the genome, either intra- or inter-
chromosomally.  The dEPT clusters to the left and right of the initial tandem duplication 
junction were smaller in size than the initial event, but their sum on each side was 
comparable to the cluster size of the initial event. An inter-chromosomal dPET cluster with 
498 dPETs connected chromosome 20 at 55 Mb (left side of the tandem duplication junction 
in Figure 3.23. C and G) to chromosome 17, while another inter-chromosomal dPET cluster 
with 370 dPETs connected chromosome 20 at 53 Mb (right side of the tandem duplication 
junction) to chromosome 17. As the number of dPETs of these two clusters were similar, it is 
conceivable that the two clusters represent the paired rearrangement points of an inter-
chromosomal translocation that inserted the junction region of the tandem-duplicated 
segment of chromosome 20 into chromosome 17. Similarly, the same tandem-duplicated 
junction appeared to be, by a separate translocation, connected to chromosome 17 and 3 
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(cluster sizes 236 and 256, respectively). Further shorter segments of this tandem duplication 
junction were disseminated to other locations on chromosomes 17 and 20 (by two pairs of 
dPET clusters with 221/149 and 181/148 dPETs, respectively; Figure 3.23.G). It is worth 
noting that the sum of relative copy numbers of the rearranged segments inferred by these 
four subordinate dPET clusters coincides well with the copy number of the tandem 
duplication on chromosome 20 (see below), suggesting that this tandem duplication junction 
is the origin for the subsequent amplification and dissemination. The locus on chromosome 
20 gains more complexity by long distance unpaired inversions (45.2-48.7 Mb and 45.8-47 
Mb) of high cluster size and further connections to the region on chromosome 17 (56-60 Mb). 
This suggests that the tandem duplication junction was the origin for the subsequent 
amplification and dissemination.  
         The dPET connectivity and PET counts together delineate a possible genealogy of 
rearrangements in the MCF-7 genome. We hypothesize that this 3.67 Mb segment in tandem 
duplication was the first rearrangement; it then probably created a state of genomic instability, 
and triggered a cascade of subsequent rearrangements that centered around the junction point 
of the initial tandem duplication, probably by providing the substance for NAHR. Such 
recombination could take place between sister chromatids to result in further linear 
amplification of this duplicated segment, or intrachromatid generating potential “double 
minute” constructs that could be further amplified and eventually inserted in other parts of the 
genome (Figure 3.23. I). 
         The extensive proliferation of this rearranged structure suggests that some driver 
element(s) were created to favor the selection of this junction segment during the 
evolutionary course of this genome. This tandem duplication juxtaposes the BMP7 gene 
immediately downstream of the ZNF217 gene (Figure 3.23. H), and this two-gene construct is 
intact in the minimal core segment that has been amplified most extensively, suggesting that 
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it was advantageous for its extensive amplification. Quantitative reverse transcription PCR 
(qRT-PCR) of BMP7 and ZNF217 proved that both genes are highly expressed in MCF-7 
(Figure 3.24), suggesting that MCF-7 cells achieve high expression of these two genes 
through high gene copy numbers. It is still not entirely understood how this two-gene locus 




    Figure 3.24. RT-PCR of BMP7 and ZNF217 in breast cancer cell lines and     
    normal breast. 
 
Expression relative to beta-actin (y-axis) of three independent experiments is shown. ZNF217 (long) 








Genomic architecture of amplified regions in SKBR3 
Similarly, the SKBR3 genome also has a few complex units of rearrangements located in 
highly amplified regions. The largest complex unit consists of 50 rearrangements (Fig. 3.6) 
The rearrangement with the highest dPET cluster count (n = 624) in this genome is also a 
large tandem duplication (9.1 Mb) and mapped to chromosome 8 at location 72.8-82 Mb 
(Figure 3.24). It is also involved in highly amplified regions and is connected to other 
rearrangement sites. Based on dPET connectivity and PET counts, we reconstructed the 
amplified regions that involved at least two levels of subordinate tandem duplications and an 
inter-chromosomal translocation that connected chromosome 8 (71.4-82 Mb, 87.2-92.6 Mb, 
109.8-129.2 Mb) to chromosome 17 (34.5-37.8 Mb) (Figure 3.25). Similar to the amplicon 
regions in MCF-7, the SKBR3 data implies that the fusion point created by the tandem 
duplication occurred early in the genealogy of this breast cancer genome and that subsequent 





Figure 3.25. Architecture and genealogy of amplifications in SKBR3. 
(A) Copy number plots of chromosomes 8 (left) and 17 (right) with amplified regions (red boxes). (B) 
Concordant tag distributions (in green) are shown for amplified genomic regions on chromosomes 8 
and 17 (top). Genomic segments between predicted rearrangement points are indicated by colored 
arrows (middle) and dPET clusters with cluster sizes greater than 90 are represented by horizontal 
lines flanked by dark red and pink arrows (bottom). Abbreviations are as described in Fig. 4. 
Deletions <50 Kb are in gray and were not considered for genomic segmentation. (C) Possible 
genealogy of amplification. TD624 occurred early (top left, rearrangement point is represented by 
dark red and pink arrows). Subsequent rearrangements have pasted TD624 in different genomic 
contexts and thereby amplified the rearrangement point. (D) Double-color FISH experiments using 
probes flanking TD624. Red represents chr8:72,695,393- 72,880,900 and green chr8:81,904,336-
82,095,683. Note the repetitive linear sequence of the two loci with double signals (filled arrow heads) 
indicating the fusion of the two loci and single signals indicating the normal genomic distance (open 
arrow head). (E) Genes flanking TD624 with STMN2, HEY1, MRPS28, TPD52, ZBTB10, and ZNF704 




Genomic architecture of amplified regions in primary tumor 
Primary tumor genomes also have extensive amplifications (Figure 3.6). For instance, breast 
tumor 14 displayed a local amplification on chromosome 9p (Figure 3.26. A) where 8 dPET 
clusters (PET counts >8) were connected to this amplified locus, including four large tandem 
duplications, two unpaired inversions, and two deletions (Figure 3.26. B). The deletion with 
the largest cluster count excises exons 2 to 6 of KDM4C (Figure 3.26. C) and the exon 1-7 
fusion was validated by RT-PCR (Figure 3.26. D). KDM4C (also known as GASC1) has been 
described as an oncogene in breast cancer (Liu et al. 2009). If translated, this truncated 
protein would lack the entire JmjN domain; have a partial JmjC domain, and an intact PHD-





Figure 3.26. The architecture of an amplified region in primary breast tumor 14. 
 (A) Concordant tag based copy number estimate for chromosome 9 indicates an amplification of the 
distal region of 9p. (B) Concordant tag distribution of chromosome 9 position 2-10 Mb (top, green 
track). Genomic segments between predicted breakpoints are indicated by colored arrows (middle) 
and dPET clusters with cluster sizes greater than eight are represented by horizontal lines flanked by 
dark red and pink arrows (bottom). Abbreviations for mapping characteristics of dPET clusters are 
described in Figure 6. (C) Genomic structure of KDM4C. Location of amplified deletion (Del25) is 
indicated by dashed vertical lines. (D) Sequencing result of RT-PCR confirms the in-frame deletion 






Breakage-fusion-bridge cycle in cancer genome 
We observed many long distance unpaired inversions in the breast and gastric cancer 
genomes, which could indicate the inversion of whole chromosomal arms, large inversions or 
inverted insertions are involved in further rearrangements, or a failure to detect the paired 
rearrangement point that would classify the event as an inversion. On the other hand, 
unpaired inversions with a relatively short distance between their breakpoints could occur 
when a DNA double strand break results in a truncated chromosome, followed by the 
replication of the DNA and the joining of the two neighboring ends by a DNA repair 
mechanism in a head to head or tail to tail fashion (resulting in a fusion of + and – strand of 
the sister chromatids, Figure 3.27. A). Due to the fusion, the two sister chromatids cannot be 
separated in mitosis and a new break could occur to initiate a new fusion. This mechanism 
has been described as breakage-fusion-bridge (BFB) cycles which was originally proposed by 
Barbara McClintock in 1941(reviewed in (Tanaka et al. 2009). In this model, a double-strand 
chromosome break generating a free DNA end is followed by DNA synthesis and sister 
chromatid formation, resulting in two identical free DNA ends. The pair of sister chromatids 
then fuse to each other in order to eliminate the free ends, which otherwise may trigger cell 
death. Following chromatid separation during mitosis, an anaphase bridge is formed, 
resulting in a further doublestrand break and re-initiation of the breakage-fusion-bridge cycle. 
A distance of a few kilobases between head to head fusion points has been reported (Bignell 
et al. 2010; Lo et al. 2002; Okuno et al. 2004). Gastric tumor 17, which had the most 
rearranged and amplified genome among the four gastric tumor samples (Figure 3.6) showed 
an accumulation of short distance unpaired inversions in the amplified regions on 
chromosomes 5, 11, 12, and 18 (Figure 3.27. B). This pattern can be explained by BFB cycles 
which are known to result in amplifications (Tanaka et al. 2009) (Figure 3.27. C-D). The 
dPET counts implied that a translocation between chromosomes 5 and 18 (cluster count, 
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n=382) preceded a double strand break and a subsequent tail to tail fusion of chromosome 5 
at 39.2 Mb by an unpaired inversion (cluster count, n=118; Figure 3.27.). Further breaks and 
fusions amplified the chromosome 5 and 18 segments. A break in a postulated second BFB 
cycle resulted in two sister chromatid fusions, which showed a larger distance between their 
breakpoints of 390 and 450 kb, respectively, and involved a loss of 1.5 Mb. The data imply 
the propagation of different populations of rearranged chromosomes, which together result in 
the amplification of the two loci. We observed a larger number of small (<10 kb) unpaired 
inversions per chromosome in the gastric cancer samples than in the breast cancer samples 
(p=0.00587). This might indicate that BFB cycles are more characteristic for gastric rather 






Figure 3.27. Accumulation of short span unpaired inversions in amplified regions of gastric 
tumor 17. 
(A) PET mapping pattern of short span unpaired inversions and the interpretation. The mapping of a 5’ anchor 
(dark red arrow) to the + strand and a 3’ anchor (pink arrow) to the – strand indicates a head to head fusion (red 
arrows) with increasing chromosomal coordinates closer to the breakpoint (top) and a 5’ – strand/3’ + strand 
mapping indicates a tail to tail fusion with decreasing chromosomal coordinates closer to the breakpoint 
(bottom). UI120 and UI118 in (B) are examples for head to head and tail to tail fusions, respectively. (B) 
Amplifications on chromosomes 5 and 18 of gastric tumor 17 are indicated by concordant tag counts (green). 
Cancer structural rearrangements with dPET cluster sizes >15 are indicated by dark red and pink arrows for 5’ 
and 3’ anchors, respectively. Abbreviations and figure structure are described in legend of Figure 6B. Unpaired 
inversions with a breakpoint distance <40 Kb are indicated by asterisks. (C) Schematic representation of an 
isolated translocation between chromosome 5 (green) and 18 (gray). Black circles represent centromeres, blue X 
represents site of recombination. Gray arrows indicate the direction of increasing genomic coordinates. (D) 
Interpretation of accumulated short unpaired inversions in amplifications by BFB cycles.  
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Figure 3.28. Architecture of amplifications of gastric tumor 17. 
Concordant tag distributions of amplified regions on chromosomes 5, 6, 11, 12, 17, and 18 are 
represented by green tracks. Rearrangement points are represented by dark red and pink arrows 
connected by horizontal lines. Rearrangement points of cancer specific dPET clusters with a size >100 
are arranged according to dPET cluster size from top (small) to bottom (large). Three unpaired 
inversions on chromosome 11 with cluster sizes <100 have been included to explain copy number 
changes. Deletions <20 kb are not displayed. 
 
Discussion 
We have comprehensively characterized SVs of 15 human cancer genomes and 2 normal 
human genomes by paired-end-tag sequencing and mapping analysis. The use of a 10 kb 
insert size for DNA-PET analysis allows the identification of breakpoints within repetitive or 
homology containing regions of a few kilobases in size and results in a higher physical 
coverage compared to small insert libraries with the same sequencing effort. The recently 
reported study by Stephens et al. (Stephens et al. 2009) on breast cancer genome structures 
using short DNA fragments may have insufficient physical coverage of the genome to map 
rearrangements in complicated genomic regions without dramatically increasing the 
sequencing coverage. Thus, long span DNA paired-end approaches such as outlined here 
represent a parsimonious and cost effective approach to comprehensively map structural 
mutations in cancers.  
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         All the five primary breast tumors are belonging to basal-like breast cancer. The 
characterization of basal-like breast cancer is the absence of oestrogen receptor (ER) 
expression, the lack of ERBB2 gene amplification, and a high mitotic index. The rapid fatal 
clinical course is the consequent of no approved targeted therapy options and poor response 
to standard chemotherapy. The poor understanding the genetic events of this tumor subtype 
limited the clinical progress (Carey et al. 2006). Recently, four DNA samples from a African-
American patient with basal-like breast cancer: peripheral blood, the primary tumor, a brain 
metastasis and a xenograft derived from the primary tumor were sequenced by next 
generation sequencing technologies (454 and Illumina, (Ding et al. 2010). The 
comprehensive analysis of these four samples identified 50 novel somatic point mutations 
and small indels in coding sequences, RNA genes and splice sites as well as 28 large 
deletions, 6 inversions and 7 translocations. Two de novo mutations, one was a missense 
mutation (T708I) in SNED1, with a mutant frequency of 37%, the other was a silent mutation 
(N2483) in FLNC with a mutation allele frequency of 18% were found only in the metastatic 
tumor, but not in primary or xenograft tumor genomes. In addition, a 26 kb deletion in MECT 
was only identified and validated in the metastasis, suggestion its de novo nature in this 
sample. The results also showed that xenograft retained all primary tumor mutations and 
displayed a mutation enrichment pattern that resembled the metastasis (Ding et al. 2010). 
Another notable finding is that two overlapping large deletions (538 kb and 515 kb in length) 
on chromosome 5, affecting CTNNA1 along with LRRTM2, MATR3, SNORA74A and SIL1, 
were found to be present in all three tumor samples. CTNNA1 was shown to be very 
important for the cell adhesion in breast cancer cells (Bajpai et al. 2009) and increased in 
vitro tumorigenic characteristics (Plumb et al. 2009). The bi-allelic deletion might have 
important function. This study demonstrated that, although additional copy number changes, 
structural variations and somatic mutations do occur during the progress of the disease, most 
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of the original mutations and structural variations present in the primary tumor are 
propagated.  
        From the data generated in this study, some characteristic patterns of SVs in cancer 
genomes including primary tumors and cancer cell lines emerged. Inversions, insertions, and 
deletions are more commonly seen in germ line SVs; whereas somatic rearrangements 
present in cancer genomes are overrepresented in tandem duplications, unpaired inversions, 
isolated translocations, and in amplified complex regions. Such distinction is likely due to 
mechanistic differences: SVs with germ line origins are meiotic recombinants, whereas 
somatic SVs may use a variety of mechanisms including mitotic DNA repair, transcription-
mediated recombination, and generation of double-minute structures (Gu et al. 2008; Kuttler 
et al. 2007; Lin et al. 2009; Murnane et al. 2004).  
        The precise and quantitative connectivity assessment of fusion points in amplified 
regions by dPET clusters provided an opportunity to delineate the genealogy of 
amplifications in cancer genomes. In the samples of breast and gastric cancer that we 
examined, we have gathered evidence to show that large tandem duplications as well as 
unpaired inversions appear to be early events triggering a subsequent cascade of extensive 
amplification centered around the junction region. Though it remains a possibility that the 
tandem duplication may simply function as a “marker” for regional genomic instability 
remains a possibility, the propagation of the precise tandem duplication through progressive 
amplification in several cancer genomes suggests that particular tandem duplications have 
“driver” function. The evolutionary signature of an initiator-amplification cycle is further 
supported by the observation in the K562 cell line where the BCR-ABL1 balanced 
translocation between chromosomes 9 and 20 has been subsequently amplified in other parts 
of the genome (Figure 2.15).  
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        It is not clear what mechanisms dictate the initial structure of the early events for 
amplification and why epithelial cancer genomes favor local duplication whereas leukemia 
genomes prefer inter-chromosomal translocation. The difference at this level may be 
associated with the spatial state of chromosome conformation in particular cell types and the 
microenvironment of selective pressure where the primary cells reside.  
        Complex rearrangements and extensive amplification are much more abundant in the 
cancer cell lines than in primary tumors. This is likely due to additional rearrangements that 
are acquired during in vitro passages of the cell lines. However, detailed analysis of these 
rearrangements could provide an evolutionary model that “amplifies” the functional 
importance of any particular rearrangement. To a degree, such a rearrangement map of a 
highly passaged cell line may represent a steady state of genome fitness for a specific cancer, 
especially for in vitro conditions.  
        It is well known that cancers from different lineages such as epithelial and mesenchymal 
origins harbor very different genetic rearrangements: balanced translocations are 
predominantly found in mesenchymal cancers, whereas complex rearrangements are a 
hallmark of mature epithelial cancers. Our focus on two epithelial cancers, breast and gastric, 
was an attempt to assess the differences between two distinct epithelial cancers that arise 
from very different epidemiologic etiologies. We found, within the limitations of sample size, 
that breast and gastric cancer genomes have some comparable structural characteristics. Both 
cancers show an enrichment of tandem duplications, unpaired inversions, isolated 
translocations and complex rearrangements. In breast and gastric cancer, tandem duplications 
are larger than other SV categories and have a higher chance of enclosing genes. However, 
gastric cancer rather than breast cancer shows signatures that are compatible with the 
breakage-fusion-bridge (BFB) model, which might suggest different mechanisms of genome 
instability.  
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        The mapping of primary tumor genomes demonstrated in this study validated the 
feasibility of using large span paired-end-tag sequencing to characterize clinical samples for 
genome structural variations. With further optimization for the current prototype of DNA-
PET analysis and continuous drop of sequencing cost, we expect this approach to be 
sufficiently robust and cost effective to be applied in clinical settings for genetic diagnostics 
















Chapter Four: Conclusions 
Summary 
In this thesis, I have demonstrated that long span DNA-PET (10 kb) is a powerful tool to 
study human cancer genomes. The use of a 10 kb insert size allows the identification of 
breakpoints within repetitive or homology-containing regions of a few kilobases in size and 
results in a higher physical coverage compared with small insert libraries (1 kb) with the 
same sequencing effort. The short span DNA-PET had only advantages to identify deletions 
smaller than 5 kb. In addition, our data also demonstrated that 10 kb library had a comparable 
resolution (114 bp vs. 377 bp in 1 kb and 10 kb library) in predicting breakpoint locations to 
a distance that can be amplified by PCR. The 20 kb insert size library had a slight advantage 
in discovering inversions and unpaired inversions compared to 10 kb insert size library but 
displayed a low sensitivity in identifying small SVs of various categories. Moreover, the 
construction of libraries with 20 kb inserts requires more genomic DNA starting material. 
The detailed characterization of SVs by long span DNA-PET libraries showed many new 
sub-types of insertions, which could help in understanding the effect and genesis of insertions 
in human cancer genomes.  
        We have applied this long span DNA-PET approach to comprehensively characterize 
the SVs of two epithelial cancers, breast and gastric cancer. Fifteen cancer genomes and two 
normal genomes were analyzed and we used a filtering approach to strongly enrich for 
somatic SVs in the cancer genomes. Our analyses revealed that most inversions, deletions, 
and insertions are germ-line SVs, whereas tandem duplications, unpaired inversions, 
interchromosomal translocations, and complex rearragements are over-represented among 
somatic rearrangements in cancer genomes. We demonstrate that the quantitative and 
connective nature of DNA-PET data is precise in delineating the genealogy of complex 
rearrangement events, we observe signatures that are compatible with breakage-fusion-bridge 
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cycles, and we discover that large duplications are among the initial rearrangements that 
trigger genome instability for extensive amplification in epithelial cancers. 
          With the rapid development of next generation sequencing technologies, whole 
genome sequencing has become an invaluable tool for obtaining a complete understanding of 
human genomic variation. In the future, personal genomic information will gain importance 
to tailor an individual’s medical care. With further optimization for the current prototype of 
DNA-PET analysis, we expect this approach to be sufficiently robust and cost effective to be 
applied in clinical setting for genetic diagnostics of cancer patients and other genetic disease 
patients.   
Further development of NGS platforms 
There are three major limitations in current second generation sequencing technologies: (1) 
the read length is short; at present, NGS only can provides 50-500 continuous basepair reads, 
much shorter compared to traditional Sanger sequencing (1000-1200 bp); (2) the coverage 
which is defined as the number of short reads that overlap each other within a specific 
genomic region is uneaven; since NGS technologies only can produce short reads and 
repetitive sequences affect the mappability of short sequences, coverage becomes a very 
important issue, especially for accurate assembly of the genomic sequence; (3) mappable, 
short reads generated by NGS technologies create many sequences that cannot be interpreted 
or “mapped” unambiguosly to the reference DNA or be accurately assembled. This is because 
a number of short reads match with many different genomic regions and are therefore not 
unique to any specific genomic region.  
        The second generation sequencing  protocols use an amplification step of DNA 
fragments by emulsion or cluster PCR, to make the light signal strong enough for reliable 
base detection by the CCD cameras. Although the PCR amplification has revolutionized 
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DNA analysis, in some cases, it may introduce error base sequences or favor certain 
sequences over others, thus changing the relative frequency and abundance of various DNA 
fragments that existed before amplification (Pareek et al. 2011a). Thus, the sequence 
determined directly from a single DNA molecule without PCR amplification will overcome 
this problem. The sequencing of single DNA molecules is now called as the “third generation 
sequencing technology” (Schadt et al. 2010). HeliscopeTM single molecule sequencer is one of 
the first techniques for sequencing from a single DNA molecule and its principle relies on 
“true single molecule sequencing” (tSMS) technology. In this tSMS technology, a poli-(A) tail 
is introduced into DNA during library preparation so that the DNA molecules hybridize to the 
poli-(T) oligonucleotides which are attached to a flow cell and simultaneously get sequenced 
in parallel reactions. The sequencing cycle consist of DNA extension with one fluorescently 
labeled nucleotide, out of four, followed by nucleotide detection with the Heliscope 
sequencer. The subsequent chemical cleavage of fluorophores allows the next cycle of DNA 
elongation to begin with another fluorescently labeled nucleotide, which enables the 
determination of the DNA sequence (Pareek et al. 2011b). The Heliscope sequencer can 
sequence up to 28 Gb in a single sequencing run (8 days) with a maximal length of 55 bases.  
       Single DNA molecule sequencing technology can read through DNA templates in real 
time without amplification and provides accurate sequencing data with potentially long-reads, 
therefore, several single-molecular DNA sequencing technologies are currently under 
development (Zhang et al. 2011). Several single molecule sequencing emerged over the last 
years: (1) Flourescence-based single-molecule sequencing is performed by identifying 
nucleotides which are phospholinked with distinctive colors. During the synthesis process, 
fluorescence emitted as the phosphate chain is cleaved and the nucleotide is incorporated by a 
polymerase into a single DNA strand. (2) Nano-technologies for single-molecule sequencing 
are based on the principle that thousands of nano-tunnels on a chip can be used to monitor the 
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movement of a polymerase molecule on a single DNA strand during replication. This 
principle comes from the observation that when a DNA strand is pulled through a nanopore 
by an electrical current, each nucleotide base (A, T, C, G) creates a unique pattern in the 
electrical current. This unique nanopore electrical current fingerprint can be used for naopore 
sequencing. Electrical base detection reads through the stretched and immobilized strand of 
DNA molecules on conductive surfaces by multiple nano-knife edge probes. Each non-knife 
edge probe specially recognizes only one nucleotide for single-molecule sequencing. (3) 
Other developing approaches for single-molecule sequencing include electron microscopy, 
ion sensor or sequencing-by-hybridization technology based on known reference sequences. 
       In summary, the third generation sequencing technologies may offer the following 
advantages over second generation sequencing: i) no PCR amplification bias, ii) higher 
throughput, iii) faster turnaround time (e.g., sequencing metazoan genomes at high fold 
coverage in minutes), iv) longer read length to enhance de novo assembly and enable direct 
detection of haplotypes and even whole chromosome phasing, v) higher consensus accuracy 
to enable rare variant detection, vi) small amounts of starting material (theoretically only a 
single molecule may be required for sequencing) and vii) low cost.  
        Besides the sequencing technologies, the full benefits of NGS will not be achieved until 
extremely high-performance computing and intensive bioinformatics support is available. 
Typically, tens or hundreds of Gbp short reads can be generated during each run in any given 
NGS platform. Given the vast amount of data produced by NGS, developing a massive data 
storage and management solution and creating informatic tools to effectively analyze data 




Challenges in cancer genome sequencing 
The quantity, quality and purity of cancer samples are normally quite different from the 
peripheral blood samples which are commonly used as germline control. Solid tumors are 
complex mixtures of cells including non-cancerous fibroblasts, endothelial cells, lymphocytes 
and macrophages that often contribute more than 50% of the total DNA. This mixture can 
mask the signal from the cancer cells and complicate the inter- and intra-tumor comparisons 
(Meyerson et al.). In addition, solid tumors are often highly heterogeneous and composed of 
different clones that have different genomes. The detection of somatic mutations in cancer 
needs mutation calling in both the tumor and the matched normal DNA, coupled with the 
comparison to a reference genome. There are two kinds of false positive genome variation 
calls: inaccurate detection of an event in the tumor, when the tumor and normal are both 
wild-type; detection of a germline event in the tumor but failure to identify it in the normal 
genome. The first type of error can be induced by sequencing error, incorrect local alignment 
or discordant alignment of paired reads. The second type of false positive mutation calls 
mainly come from insufficient coverage to fail detect the germline alleles that differ from the 
reference sequence (Meyerson et al. 2010).  
      Single-cell genomic methods have the capacity to resolve complex mixtures of cells in 
tumors. Recently a new technology called single nucleus sequencing (SNS) had been 
developed by Navin and colleagues (Navin et al. 2011b), in which three technologies are 
combined including next generation sequencing (NGS), fluorescence-activated cell sorting 
(FACS) and whole genomic amplification (WGA). The SNS method has been used to 
investigate tumor population structure and evolution in two human breast cancer cases. Three 
distinct clonal subpopulations isolated from 100 single cells of a polygenomic tumor may 
represent sequential clonal expansions. One hundred single cells from a monogenomic 
primary tumor and its liver metastasis showed a single clonal expansion formed by the 
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primary tumor which seeded the metastasis. This study demonstrated that we can make 
inferences about the evolution and spread of cancer by the copy number profiles from 
sequencing a single cell. The identification of pseudodiploid cells showed that single cell 
sequencing methods can identify cell types which could not be detected by previous methods 
(Navin et al. 2011b).  
       Single cell sequencing methods provide an unprecedented view of the genomic diversity 
within tumors and provide the means to detect and analyze the genomes of rare cancer cells. 
Although the cancer genome studies with bulk tissue samples can provide a global spectrum 
of mutations, they cannot determine whether all of the tumor cells contain the full set of 
mutations, or different subpopulations contain subsets of these mutations that in combination 
drive tumor progression. Furthermore, single cell sequencing probably can greatly improve 
our fundamental understanding of how tumor evolve and metastasize. The future medical 
application of single cell sequencing will be in early detection, monitoring circulating tumor 
cells (CTCs) during treatment of metastatic patients and measuring the genomic diversity of 
solid tumors. However, there are still many challenges ahead of single cell sequencing: i) the 
low coverage of the human genome (6%); ii) the detection of copy number variation only, but 
not structural variations due to chimeric products generated by amplication; iii) the need to 
profile hundreds of single cells quickly and at a reasonable cost; iv) the limitation on frozen 
tumor samples but not paraffin embedded samples. When future innovations allow whole 
genome sequencing of single tumor cells, oncologists will also be able to obtain the full 
spectrum of genomic sequence mutations in cancer genes from scarce clinical sample. These 
methods are likely to improve all three major themes of oncology: prognostics, diagnostics 
and chemotherapy, ultimately improving the treatment and survival of cancer patients (Navin 
et al. 2011a).  
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         In conclusion, all the pioneer studies indicated that cancers typically carry a few 
consistent and functionally characterized abnormalities, companied with tens to thousands of 
other changes that are rear or unique to the individual tumor with little known. We should 
understand which genes contribute to tumorigenesis or progression and how these changes 
happened during tumor evolution and interact with the tumor microenvironment ─ and 
therefore how it regulates each tumor’s behavior and response to therapy. All these 





















Chapter Five: Materials and methods 
Note: Except for the very first few libraries run by Forster City, ABI, USA, all sequencing 
described here was performed by the Sequencing Team of Genome Technology and Biology by Wei 
Chia-Lin and Xiaoan Ruan, Genome Institute of Singapore, Singapore. The members of the 
sequencing team are Herve Thoreau (lab manager), Dawn Choi, Low Hwee Meng, Ong Chin 
Thing (Jo), Leong See Ting, Adeline Chew, Lee Yen Ling, Poh Tong Shing and Lim Kian Chew. 
 
Materials and Methods used in chapter 2 
Cell culture and genomic DNA extraction 
MCF-7 (ATCC# HTB-22TM), HCT116 (ATCC# CCL-247TM) and K562 (ATCC# CCL-
243TM) were grown under standard culture conditions and harvested at log phase. The 
genomic DNA was extracted by Blood & Cell Culture DNA Midi Kits (Qiagen) according to 
the manufacturer’s instruction. 
 
Library construction and sequencing 
We randomly sheared up to 50 µg of genomic DNA to 1 kb, 10 kb and 20 kb fragments by 
HydroShear (Genomic Solutions Inc) according to the manufacturer’s instruction. The 
fragmented DNA was methylated using EcoP15I (NEB) and end polished by End-ItTM DNA 
End-Repair kit (Epicentre Biotechnologies). SOLiD EcoP15I CAP adaptor (Applied 
Biosystems) which contains the EcoP15I restriction site was blunt-end ligated to the two ends 
of DNA fragments and the ligation products were size-selected on an agarose gel. The small 
DNA fragments (1 kb) were purified by QIAquick Gel Extraction Kit (Qiagen) and large 
DNA fragments (10 kb and 20 kb) were purified by QIAEX II Gel Extraction Kit (Qiagen). 
Up to 1 µg of gel selected DNA fragments were circularized with the biotinylated SOLiD 
Internal Adaptor (Applied Biosystems) at 0.1 ng/µl final DNA concentration and the 
uncircularized DNA fragments were removed by Plasmid-SafeTM ATP-Dependent DNase 
(Epicentre Biotechnologies). The remaining circularized DNA fragments were digested by 
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EcoP15I (NEB) to release the 25-27 bp di-tags from genomic DNA fragments. Di-tag 
constructs were end repaired, bound to streptavidin beads and washed. SOLiD sequencing 
adaptors (Applied Biosystems) were ligated and di-tag constructs were amplified with SOLiD 
PCR primers (Applied Biosystems) by a 16-cycle PCR. High-throughput sequencing of the 2 
x 25 bp libraries was performed on SOLiD sequencers according to the manufacturer’s 
recommendations (Applied Biosystems). Note: libraries IHH026, IHK016 and IHK017 were 
constructed by Zhang Zhenshui; IHK002, IHK004 and IHK007 were constructed by Poh Hui Mei, 
respectively. Genome Institute of Singapore, Singapore. 
 
PET sequencing analysis 
Mapping, pairing and rescuing of sequence di-tags  
The paired tags designated as R3 and F3 were mapped individually to the reference sequence 
(hg18, NCBI build 36) in color space by the ABI SOLiD pipeline Corona Lite (Applied 
Biosystems). Contigs of the reference sequence with unresolved location (random_chr) and 
alternative MHC haplotypes were excluded from the reference for mapping since they caused 
ambiguous mapping due to high sequence similarity to other sequences in the reference. The 
pairing and rescuing procedure can be divided in four steps. 1) For each bead (di-tag 
amplicon unit on a sequencing slide) collect and match all R3 and F3 mapping locations with 
up to 2 mismatches (for a 2x25 bp library). 2) If both R3 and F3 tags are present and at least 
one has hit(s) to the reference go to pairing, otherwise discard the bead. 3) Pairing: if both 
tags have matches to the reference, try all R3/F3 combinations to see if there is a single pair 
combination with correct orientation and specified insert range. If there is such a combination 
report it as AAA indicating that both tags are on the same chromosome, same strand, read in 
the same direction, are in the correct order [R3 is 5’ of F3]; and within 20 kb of each other 
(for 10 kb library, 5 kb for 1 kb library and 40 kb for 20 kb library); if there is more than one 
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pair of AAA, discard the bead. If there is no AAA, go to rescue. 4) Rescue: anchor each hit to 
the reference and search nearby sequence for AAA hits with up to 4 mismatches. If a single 
AAA can be found, report it as AAA; if there are more than one pair of AAA, discard it. If no 
AAA can be found, paired reads are classified according to ABI SOLiD nomenclature. 
Redundant PETs which had the same starting points for both tags were believed to be derived 
from the same PCR product of the library amplification step and were removed from further 
analysis. Non-AAA PETs were defined as redundant if the starting points of both tags were 
within +/- 2 bp. 
 
PET classification 
Based on ABI SOLiD pairing report, we further separated all the PETs into concordant PETs 
(cPETs) and discordant PETs (dPETs). cPETs were defined as those where both tags mapped 
to same chromosome, same strand, in the correct 5’ to 3’ ordering and within expected span 
range. The span range was determined by the following process. The span distribution of all 
AAA PETs was plotted. The distribution was smoothened by averaging values across 
overlapping windows with the size of 0.1 x standard deviation (µ) of the average span (within 
0-20,000 bp, where µ above and below average was calculated separately). Smoothening for 
each point x was done by averaging the values across the window [x - µ/2 , x + µ/2]. Then the 
gradient at each position along the distribution was calculated by gradient(x) = 
(smoothened_dist (x + µ/2) - smoothened_dist (x - µ/2) ) / µ. The minimum span point should 
be the point left of maximum gradient where gradient reaches 0. The PETs which were 
rejected by cPET criteria were classified as dPETs. These were further split into five distinct 
categories; (i) two tags mapped on different chromosomes, (ii) two tags mapped on the same 
chromosome, but different strand, (iii) two tags mapped on the same chromosome, but wrong 
order (5’ downstream of 3’), (iv) two tags mapped on the same chromosome, same strand, 
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correct order, but with larger span distance than 1.1x the maximum library size, (v) two tags 
mapped on same chromosome, same strand, correct order, but with smaller span distance than 
the minimum library size.  
 
Clustering of dPETs 
Discordant PETs may result from either inherent SVs in the sequenced genome or due to 
ligation errors in the library construction process. To filter out those from ligation errors, we 
identified those discordant PETs that occurred together to form clusters. Prior to clustering, a 
form of ‘normalization’ was carried out to convert PETs from one strand to the other, so that 
all discordant PETS were perceived to have come from a single strand. For each discordant 
mapping, both the original mapping and its reverse complement mapping were considered. 
One of the two mappings was selected according to following hierarchy of preferences. i) 
Mapping with lower chromosome value for 5’ was chosen. ii) If both chromosomes were 
same, mapping which results in 5’ tag mapping to ‘+’ strand was chosen. iii) If no such 
mapping existed, mapping which resulted in 5’ tag having smaller coordinate was chosen.  
 
        To cluster different dPETs which span the same fusion point, the following procedure 
was applied: the mapping location of the 5’ and 3’ tags of a given dPET was extended by the 
maximum insert size of the respective genomic library in both directions to create 5’ and 3’ 
searching windows. If the 5’ and 3’ tags of a second dPET mapped within the 5’ and 3’ 
searching window of the first dPET, the two PETs were defined as a cluster of the count 2 
and the 5’ and 3’ searching windows were adjusted so that they contained the tag extensions 
(by the maximum library size) of the second dPET. dPETs which subsequently mapped with 
their 5’ and 3’ tags within the 5’ and 3’ searching windows, respectively, were assigned to 
this cluster and the windows were adjusted, if necessary. The number of dPETs clustering 
 132 
together around a fusion point was represented by the cluster count. The genomic region 
which was covered by the 5’ tags of a cluster was defined as the 5’ anchor and the genomic 
region which was covered by the 3’ tags of a cluster was defined as the 3’ anchor. Note: PET 
sequencing analysis was performed by Pramila Ariyaratne, Genome Institute of Singapore, 
Singapore. 
 
Identification of structural variations 
The characteristics of the dPET clusters were used to determine individual classes of 
structural variations. dPET clusters with an insert size which was larger than the size of the 
genomic library were defined as deletions. Tandem duplications were characterized by 
clusters where the 3’ tags preceded the 5’ tags of a mapped cluster (wrong ordering). 
Inversions were identified by two clusters of the category ‘same chromosome, different 
strand’ where the genomic regions which were covered by the clusters overlapped. Different 
kinds of insertions were defined by two dPET clusters which indicated that a genomic 
fragment (donor) has been inserted in a certain position (recipient). The two anchor regions 
on the recipient DNA strand were allowed to be at most twice the maximum library insert 
size apart from each other. Isolated translocations were characterized by clusters where 5’ 
and 3’ tags of a cluster mapped on different chromosome. Balanced translocations were 
identified by two isolated translocations clusters and the two genomic regions exchanged. 
 
Superclustering  
To determine the neighborhood of a breakpoint, the start and end points of each dPET cluster 
anchor region were extended by the maximum insert size of the respective genomic library as 
search windows. If windows of neighboring clusters overlapped with each other, dPET 
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clusters were grouped together into a supercluster. The procedure allowed an indirect 
connection of cluster A via B to C. The number of dPET clusters that could be joined 
together into a supercluster was represented by the supercluster size. In cases where >3 dPET 
clusters were interconnected, the breakpoint pairs were classified as ‘complex’ (intra- and 
inter-chromosomal). This method had two benefits: 1) it allowed the separation of complex 
regions and allowed a more reliable SV calling for the non-complex SVs, and 2) it gave an 
overview of which rearrangement points (and thereby regions) collectively formed an 
amplification. Since an amplified region can contain a number of different loci, its joint 
nature is neither obvious by looking at the copy number itself nor by investigating individual 
dPET clusters.  
 
Comparison of libraries with different insert sizes  
The comparison of dPET clusters across different insert size libraries was performed based 
on an overlap of the 5’ and 3’ anchor region extended by the individual library insert size. We 
started from the 10 kb library in MCF-7 and HCT116 and the 20 kb library in K562. For any 
given 10 kb or 20 kb isolated dPET cluster (supercluster count ≤3), the 5’ and 3’ anchor 
regions of the cluster was extended by the maximum length of the library towards the 
breakpoints to create a search window. If the 5’ and 3’ anchor regions of a dPET cluster from 
other insert size libraries which belonged to the same SV type fell into the search window, 
the clusters would be grouped as a common SV. If no other cluster could be found in the 
search window, the cluster would be categorized as a SV specific to that insert size library. 
Note: SVs identification, superclustering and different insert size libraries cross-




Breakpoint confirmation by genomic PCR and Sanger sequencing 
We validated a subset of breakpoints using genomic PCR. Primers were designed to span the 
breakpoint predicted by dPET clusters using repeat–masked human genome assembly (March 
2006 assembly, Build 36). The maximum PCR product was 10 kb. PCR was carried out with 
JumpStartTM REDAccuTaq LA DNA Ploymerase (Sigma-Aldrich) in a 50 µl reaction volume 
and with 20 ng of genomic DNA as the template. The following program was used: 1) Initial 
denaturation at 96°C for 30 sec, 2)15 cycles of 15 sec at 94°C, 30 sec at 58°C, 10 min at 68°C, 
3) 25 cycles of 15 sec at 94°C, 30 sec at 55°C, 10 min at 68°C, 4) 68°C for 20 min. 
Fragments up to 10 kb in size were visualized by agarose gel electrophoresis. PCR products 
with single band at the expected size range were purified by QIAquick PCR Purification Kit 
(Qiagen), sequenced by conventional Sanger capillary methods and the resulting sequences 
were aligned to the reference sequence to identify breakpoints. We then compared breakpoint 
coordinates from Sanger sequencing with the breakpoint coordinates predicted by dPET 
clusters and determined a median resolution for each library size.  
 
Copy number analysis 
For estimation of copy number, the genome was divided into non-overlapping windows of 
equal size, which could be set as a parameter and depended on the overall coverage of the 
sequenced data. To determine the different mappability of reads in each window due to 
varying uniqueness across the genome, paired-end-tags of 1x genome coverage were 
simulated by creating randomly distributed fragments along the reference genome with size 
distribution similar to the actual experimental library and extracting the tags at both ends of 
the fragments. Sequencing and ligation errors of 1% and 5%, respectively, were also added to 
generate the simulated library. The simulated tags were then mapped to the reference genome 
 135 
and paired using the same Applied Biosystems SOLiD mapping and pairing pipeline. 
Subsequently, the tag density in each window was corrected for its mappability by computing 
the ratio of number of mapped tags of the experimental library to the simulated library within 
the window. cPET tags were used for copy number estimation. Windows overlapping clusters 
of dPET tags were omitted for copy number estimation because the cPET tag count in these 
windows was no longer representative of the copy number. 
        The tag density in each window was corrected for GC bias according to the GC bias 
distribution of the DNA fragments observed in the DNA-PET library. The bias was 
calculated by taking the ratio of proportion of cPETs of each experimental library to the 
simulated library of corresponding size for each GC range of every 1 % (Figure 5.1). The 
variation in GC bias across the libraries is likely to be related to slight condition variations in 
the library construction procedure. Thus, for each DNA-PET library, the tag density in each 
10 kb window of a given GC content was corrected for its bias based on the respective GC 
content bin. To estimate the copy number independently of the availability of a matched 
sample, we normalized the corrected tag density such that the median copy number was two 
copies. This is a reasonably valid assumption, as we would expect most parts of the genome 
to be normal. Due to significant amount of noise as a result of non-uniform sampling 
throughout the genome, the copy number estimates in the windows were smoothened to 
identify copy number segments and change points using a binary circular segmentation 
algorithm (SD=2) originally developed for aCGH data (Venkatraman et al. 2007). Note: copy 




Figure 5.1. Distribution of GC bias of 17 DNA-PET samples. 
 
The ratio of the observed numbers of cPETs to the simulated library (y-axis) within 10 Kb windows is 




Fluorescence in situ hybridization (FISH)  
FISH was performed as described by Koichiro (Inaki et al. 2011). In brief, nuclei were 
harvested by treating cells with 0.75M KCl for 20 min at 37°C and dropped on slides after 
few fixations. BAC DNA probes were labeled by nick translation in the presence of biotin-
16-dUTP or digoxigenin-dUTP using Nick Translation System (Invitrogen). Prior to 
hybridization, slides were treated with 0.01% pepsin at 37°C for 5 min followed by 1 X PBS 
rinse, 1% formaldehyde 10 min treatment, 1 X PBS rinse (5 min) and dehydration through 
ethanol series (70%, 80%, and 100%). Denaturated probes were applied to these pre-treated 
slides and co-denaturated at 75°C for 5 min and hybridized at 37°C overnight. After post-
hybridization washes and blocking, slides were revealed with avidin-conjugated fluorescein 
isothiocyanate (FITC) (Vector Laboratories). Slides were mounted with vectashield and 
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observed under epifluorescence microscope. Note: FISH experiment was performed by Valere 
group, Genome Institute of Singapore, Singapore.  
 
Reconstruction of genome structure by fusion point guided concatenation 
Segmenting of the reference genome into contigs was done on the basis of breakpoints 
identified by dPET clusters and by identifying additional breakpoints with no physical cPET 
coverage. Contigs consecutive on the reference genome were then connected by a reference 
edge in the presence of connecting cPETs. Correspondingly, contigs linked by dPET clusters 
were represented by dPET edges where the edges were weighted by the count of the cluster. 
Locally amplified regions were then identified in the following way: firstly, the dPET edge 
with the highest weight was selected and the adjacent contigs to this edge were added to the 
amplicon graph. Then, for each contig in the graph, its neighbors were also added using both 
reference and dPET links as long as the neighbors were considered amplified (cPET 
estimated copy-number greater than 2). An amplicon graph was grown until no more contigs 
could be added in this fashion. The process was then repeated on the unused dPET edges, till 
none remained, resulting in a set of local amplicon graphs and only graphs with more than 
two contigs were considered further. Note: fusion point guided concatenation analysis was 









Materials and Methods for Chapter 3 
Note: The Materials and Methods for Chapter 2 and 3 have a number of overlaps; where is occurs, 
Chapter 3 refers to Chapter 2, and the description in Chapter 2 includes slight modifications used 
in Chapter 3.  
 
Cell culture  
The human cell lines, SKBR3 and T47D were obtained from the American Type Culture 
Collection (ATCC), TMK1 was kindly provided by Dr Y. Ito (National University of 
Singapore; Agency for Science, Technology and Research, Singapore).  
 
Clinical tumor samples  
Tissue samples were obtained from five patients who had undergone surgery for breast 
cancer at the University Hospital Stockholm, Sweden, and from four patients who had 
undergone surgery for gastric cancer at the National University Hospital of Singapore. All 
breast tumors were from European patients and belonged to the basal-like subgroup based on 
micro array expression data. These samples were anonymized prior to sequencing and 
analysis therefore no clinical data are available. The gastric cancer specimens were from four 
male patients with advanced-stage gastric cancer (TNM stage 3a –gastric tumor 28, stage 3b 
–gastric tumor 26, stage 4 –gastric tumors 17 and 38, respectively) of Chinese (gastric tumors 
17, 28, 38) and Malay (gastric tumor 26) ethnicity. Histologically, gastric tumor 26 was a 
Lauren classification diffuse-type, poorly differentiated signet ring cell carcinoma, while 
gastric tumors 17 and 38 were Lauren classification mixed-type, poorly-differentiated signet 




Genomic DNA extraction  
The genomic DNA of cell lines was extracted by Blood & Cell Culture DNA Kits (Qiagen) 
and DNA of tumor samples was extracted using AllPrep DNA/RNA Mini Kit (Qiagen) 
according to the manufacturer’s instruction.  
 
DNA-PET library construction, sequencing and mapping  
All libraries except gastric tumor 17 were constructed by the method described in chapter 2. 
The gastric tumor 17 was constructed by Long-Mate-Paired Library Construction method. 
Similar as the EcoP15I method, but LMP CAP adaptors (Applied Biosystems) with only a 
single 5’ phosphorylated end were ligated to the hydro-sheared DNA, thus creating a nick on 
each strand after circularization of the DNA. Both nicks were translated >50 bp into the 
circularized genomic DNA fragment by DNA polymerase I, and paired-end tags of >50 bp 
were released by T7 exonuclease and S1 nuclease. SOLiD sequencing adaptors (Applied 
Biosystems) were ligated to the fragments and the ligated mixture were amplified with 
SOLiD PCR primers (Applied Biosystems) by a 13 cycles PCR. Finally 250-300 bp 
fragments were selected to generate mate paired sequencing libraries with average target 
genomic DNA on each end around 90bp by purified from PAGE gel and use as sequence 
template. The 2 x 50 bp sequencing was performed exactly according to the SOLiD 3 system 
Instrument Operation Guide and using the reagents from Applied Biosystems.  
        For all samples, one DNA-PET library was constructed and sequenced on one slide of 
SOLiD v2, except for Breast tumors 5, 13, and 14 for which two slides were sequenced. 
Gastric tumor 17 was sequenced on one SOLiD v3 slide. For MCF-7 and K562, two libraries 
were constructed and for HCT116, three libraries were constructed and the sequencing data 
was combined for downstream analysis. For K562, the second library was constructed with 
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Solexa adapters and was sequenced by nine lanes 2 x 36 bp of Solexa (Genome Analyzer II). 
The Solexa data was trimmed to 27 bp. All sequences have been submitted to the Gene 
Expression Omnibus (GEO) data base at National Center for Biotechnology Information 
(NCBI). 
      Sequence tags were mapped to the human reference sequence (NCBI Build 36), allowing 
two color-code mismatches for 25-bp reads and six mismatches for 50-bp reads and paired 
using the SOLiD System Analysis Pipeline Tool, Corona Lite (Applied Biosystems). Note: 
libraries IHB005, IHB013, IHB014, IHS012, IHT008, IHH027, DHG003, IHG005, IHG006, 
IHG009 and IHT009 were constructed by Audrey Teo. Genome Institute of Singapore, Singapore. 
 
Define dPET cluster count 
To define the dPET cluster count which provides enough confidence to call an SV, we used 
two approaches for two different categories of noise.  
1) False deletion calls based on an increase of stretched (long insert) PETs  
To account for the possibility of stretched PETs leading to deletion artifacts, we estimated the 
expected number of false-positives as follows: for each library we computed a “stretch rate”, 
S, as the proportion of library PETs that is considered stretched. For a cluster count c, the 
probability of obtaining a cluster of that count from stretched PETs is then given by Sc and 
this can be Bonferroni-corrected by the number of dPET clusters reported for a library to get 
an estimate for the expected number of false-positive clusters. Based on this model, the 
expected number of false-positive dPET clusters of count 3 or higher was <10-4 for all 
libraries (Table 5.1). 
2) Noise model for chimeric ligation and p-value calculation  
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The noise in DNA-PET data is mainly from random ligation. The null hypothesis assumes 
that, each DNA fragment has an equal chance to ligate with any other fragment to form a 
chimeric DNA-PET in a random and independent manner. Under this random model, the 
number of DNA-PETs that link two DNA fragments follows a hyper-geometric distribution. 
The formula is provided in Equation 1. One advantage of this model is that both PET 
frequency and the enrichment of the anchors are taken into account. 
 
Equation 1 considers a library with N DNA-PETs (where each DNA-PET corresponds to a 
pair of reads). Consider two DNA fragments RA and RB and let cA and cB  to be the number of 
reads mapping on RA and RB, respectively, where cA,, cB << N. Equation 1 gives the 
probability of choosing IA,B ends from cA ends of Region RA to form IA,B  DNA-PET between 
Region RA and Region RB , when cB ends are randomly chosen from 2N ends as anchors in 
Region RB. By this, we were able to compute a p-value to test if IA,B , the number of DNA-
PETs between RA and RB, were over-represented. The p-values were corrected by the 
Benjamini and Hochberg method for multiple hypothesis testing (Benjamini and Hochberg 
1995) as false discovery rate (or Q-value).  
       dPET clusters with smaller PET counts are more likely to be generated by random, than 
clusters with the larger PET counts. As a result, we assumed that the clusters with smaller 
PET counts were noise generated from random ligations, while the dPET clusters with larger 
PET counts were true signals generated from real SVs. The Q-value was used to classify the 
noise and true signals. To determine a reasonable cutoff between noise and true dPET 
clusters, we estimated the Area-Under-Curve (AUC) from Receiver Operating Characteristic 
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(ROC) curve for dPET cluster size cutoffs 2 to 10 (Figure 5.1). PET cutoffs 2 and 3 have the 
largest AUC values. Based on these rationales, we used a general dPET cluster size ≥3 to 
identify SVs acknowledging higher false discovery rates (FDRs) for the smaller clusters. 
Individual FDRs for each cluster based on the hypergeometric model are given in Appendix 
Table). Note: this analysis was performed by Li Guoliang, Genome Institute of Singapore, 
Singpaore.
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Table 5.1: Expected numbers of long insert dPET clusters 






P-value3)  E-value4)  
IHH027  European  0.00178019 7400-10977  12074 666 5.64E-09 3.76E-06 
IHH022  African  0.00626796 7132-9854  10839 356 2.46E-07 8.77E-05 
IHB001  Breast tumor 1  0.00168624 8323-12436  13679 313 4.79E-09 1.50E-06 
IHB002  Breast tumor 2  0.00431883 7742-12163  13379 426 8.06E-08 3.43E-05 
IHB005  Breast tumor 5  0.0064154 8109-12120  13332 242 2.64E-07 6.39E-05 
IHB013  Breast tumor 13  0.0017668 4012-6325  6957 957 5.52E-09 5.28E-06 
IHB014  Breast tumor 14  0.00474705 7592-12520  13772 434 1.07E-07 4.64E-05 
IHM005006  MCF7  0.001928085 8099-16217  17838 1047 7.17E-09 7.50E-06 
IHS012  SKBR3  0.00134481 7229-9639  10602 1145 2.43E-09 2.78E-06 
IHT008  T47D  0.00571014 7816-11617  12778 376 1.86E-07 7.00E-05 
DHG003  Gastric tumor 
17  
0.00184182 8630-11310  12441 1126 6.25E-09 7.04E-06 
IHG009  Gastric tumor 
26  
0.00316919 8108-11653  12818 586 3.18E-08 1.87E-05 
IHG005  Gastric tumor 
28  
0.00375142 8152-11786  12964 1238 5.28E-08 6.54E-05 
IHG006  Gastric tumor 
38  
0.0029249 7561-11503  12653 550 2.50E-08 1.38E-05 
IHT009  TMK1  0.00155585 8760-11920  13112 1253 3.77E-09 4.72E-06 
IHH003020026  HCT116  0.00456048 7200-11780  12958 883 9.48E-08 8.38E-05 
IHK006007  K562  0.00140964 6846-10248  11272 939 2.80E-09 2.63E-06 
1)
 Proportion of PETs which are longer than the long span dPET cutoff  
2)
 To define a long span dPET, the maximum cPET value is multiplied by 1.1  
3)
 Probability of Sc, with S=stretch rate and c=cluster size (set to 3 for all libraries)  
4)




Figure 5.2. A. Area-Under-Curve (AUC) from Receiver Operating Characteristic 
(ROC) curve for dPET cutoffs 2 to 10 of nine DNA-PET samples. 
dPET cluster size cutoffs are shown on the x-axis, AUC is shown on the y-axis. Highest AUC 








Figure 5.2. B. Area-Under-Curve (AUC) from Receiver Operating Characteristic 
(ROC) curve for dPET cutoffs 2 to 10 of eight DNA-PET samples. 
dPET cluster size cutoffs are shown on the x-axis, AUC is shown on the y-axis. Highest AUC 
value indicates best model (here dPET cluster count cutoff) for highest true positive vs. false 
positive ratio. 
 
SNP and sequencing error simulation for mapping and clustering  
 
To investigate if and to what extent sequencing errors, SNPs, and point mutations result 
in false positive SV calls in our pipeline, we simulated 25 bp paired-end-tags of 3x 
(sequence) genome coverage by creating randomly distributed 9.5 kb fragments (with a 
typical size distribution) along the reference genome with a point mutation rate of 0.001 
and sequencing errors taken from two sequenced libraries (IHH027 [European] and 
IHT009 [TMK1]). The two simulated libraries gave 120-fold and 123-fold physical 
coverage, respectively, which was higher than the average coverage of 81-fold for the 17 
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analyzed genomes. The two simulations resulted in 128 and 133 dPET clusters, 
respectively, which passed our quality criteria. Since the SV calling is dependent on the 
coverage, the absolute numbers of artificial clusters is expected to vary according to the 
physical coverage. In the 17 genomes, we identified on average 737 dPET clusters (666 
and 356 in the two normal control samples). This suggested that ca. 18% (133/737) of the 
15 predicted SVs in this study are false positives due to SNPs, point mutations, and 
sequencing errors. We intersected the dPET clusters of the two simulations with the SV 
predicting clusters of the 17 analyzed genomes. Of the simulation based clusters, 27 and 
29, respectively, matched DNA-PET clusters of the 17 genomes. We indicated these 
clusters in Appendix Tables as artifacts (‘sim10kb25bpIHH027’ and 
‘sim10kb25bpIHT009’). Note: this analysis was performed by Niranjan Nagarajan, Genome 
Institute of Singapore, Singpaore. 
 
Cross-genome comparison 
Comparison of clusters across different genomes was performed based on an overlap of 
the 5’ and 3’ anchor regions extended by 10 kb on both sides. If the 5’ anchor region of a 
cluster from a second library was overlapping with the 5’ extended anchor region of a 
cluster of the first library and the same was true for the 3’ anchor regions, the two clusters 
were grouped together and the 10 kb extension of the anchor regions were adjusted 
according to the outermost start and end anchor coordinates. Breakpoint locations of the 
pooled coordinates were used to compare the identified SVs with SVs in the database of 
genomic variants (http://projects.tcag.ca/variation/) (Iafrate et al. 2004), paired-end 
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sequencing studies of noncancer individuals (Kidd et al. 2008; Korbel et al. 2007) and 
paired-end sequencing data of 24 breast cancer genomes (Stephens et al. 2009). The 
fraction of an SV that overlapped with another event was calculated by the percentage of 
overlap relative to the larger event. Gene annotations was based on RegSeq Genes 
downloaded from UCSC (http://genome.ucsc.edu/) (Rhead et al. 2010) on May 14, 2009 
using library-specific breakpoints. Note: this analysis was performed by Charlie Lee, 
Genome Institute of Singapore, Singapore.  
 
Sequence features at the breakpoints of SVs 
To investigate for the presence of potential sequence homology between paired 
breakpoints, we extracted sequences 10 kb up- and downstream around predicted 20 
breakpoints from the human reference genome at University of California-Santa Cruz 
(UCSC) Genome Bioinformatics (hg18, http://genome.ucsc.edu/, (Kent et al. 2002). The 
pairs of 20 kb sequences associated with each dPET cluster were then aligned by BLAST 
(bl2seq, (Altschul et al. 1990). This usually resulted in multiple alignments and we used 
the one with the highest score (defined as "BLAST score"). The distribution of BLAST 
scores obtained was compared with the distribution obtained from 1,000 randomly 
chosen 20 kb segments of hg18. Less than 3.25% of the random pair alignments resulted 
in BLAST scores >300 (data not shown) and this threshold was selected to identify pairs 
of breakpoints with “significant” homology. These regions with significant homology 
were further annotated using genomic features from the UCSC genome browser such as 
segmental duplications (SDs) and L1 repeats. Note: this analysis was performed by Zhao 
Hao, Genome Institute of Singapore, Singapore. 
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Sequence similarity of breakpoint pairs by BLAST  
 
A dilemma of genome studies using short read sequencing data is that two genomic 
regions A and B, which show sequence homology, can cause mapping artifacts if reads of 
region A map better to region B due to errors in sequencing or in the reference sequence 
or due to the presence of SNPs. On the other hand, it seems unwise to ignore all dPETs 
which connect two regions with high sequence homology since sequence homology is 
considered a possible mechanism for NAHR (Gu et al. 2008). We therefore annotated the 
dPET clusters with an additional pair-wise Blast analysis (BlastScore1 in Appendix Table) 
in which the 5’ anchor region of a dPET cluster plus a 15 kb extension toward the 
breakpoint was aligned to the paired 3’ anchor region plus 15 kb extension (this is a 
modification of the Blast analysis shown in Figure. 3.19 where 10 kb up- and 
downstream of each breakpoint have been aligned). This annotation may be used to 
prioritize SVs for downstream validation of predicted fusion genes (Inaki et al. 2011). 
SVs with high sequence homology are difficult to validate by PCR due to hindered 
unique primer design and possible amplification artifacts based on cross-priming of 
heterogeneous extension products. Twenty-one percent of all SVs (2,635/12,537) had a 
sequence homology between their breakpoint regions which resulted in a Blast score 
≥1,000, whereas 15% of the cancer SVs (957/6,410) showed high sequence homology. 






Copy number of dPET clusters  
 
It is desirable to connect a copy number value with a dPET cluster count. This, however, 
cannot be achieved by the same method which we used for copy number estimation based 
on the cPET tags, since the mapping of dPET is more stringent in the Corona Lite SOLiD 
pipeline (a process termed ‘rescuing’ favors paired mapping of cPETs). Despite these 
limitations, it is possible to use the cPET based copy number information within an 
amplified region and correlate it with the dPET cluster counts of this region. The copy 
number of the high copy regions of the BMP7 and ZNF217 loci in MCF-7 can be 
estimated at 47 and 32 copies, respectively, based on the cPET tags. Both regions are 
connected by the largest dPET cluster of size 1,176 (TD 1,176). Considering the region 
with the lower copy number and subtracting arbitrarily 2 copies of the hypertriploid to 
hypotetraploid cell line as not connected by this cluster, there might be 30 copies of the 
rearrangement point correlated with the cluster size of 1,176 (ca. 39 dPETs per copy for 
this particular region). This suggests that ca. 25 of the 30 copies of TD 1,176 (Figure 3.23) 
were pasted in the four genomic surroundings illustrated in Figure 3.23. Note: this analysis 
was performed by Woo Xing Yi, Genome Institute of Singapore, Singapore. 
 
Quantitative polymerase chain reaction (qPCR)  
 
qPCR was performed as described by Inaki et al. (Inaki et al. 2011). Primers used were as 
follows: 5’-TCCCTGGAGAAGAGCTACGA-3’and 5’-
AGGAAGGAAGGCTGGAAGAG-3’ for ACTB (ACTB), 5’-
 150 
GCCTGCAAGATAGCCATTTC-3’ and 5’-TGGGTGGAAGAATTCCTTGT-3’ for 
BMP7, 5’-TCTGACCCAACAGTCCC-3’ and 5’-CTGGAGACAAGGGATTTCC-3’ for 
ZNF217 (long), 5’-GGAAGGTGGTTCTGAAGACG-3’ and 5’-
TGAACGGAAAAACTTTCCACA-3’ for ZNF217 (short). Each Ct value was subtracted 
by ACTB Ct value (dCt) and relative expression level was calculated as 2(-dCt). Note: this 
analysis was performed by Koichrio Inaki, Genome Institute of Singapore, Singapore. 
 
Statistical analysis  
A two-tailed x2 test was used to test for differences between the fractions of cancer and 
normal breakpoints with sequence homologies, and to test whether the proportion of 
normal and cancer breakpoints in gene deserts, genes and regulatory regions was in 
accordance with the size proportion of the respective regions relative to the human 
genome. Mann-Whitney U Test was applied to compare SV size distributions between 
normal samples and the different cancer categories and to test for differences between the 
frequency of short unpaired inversions per chromosome of breast and gastric cancer 
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